Comparison	O
with	O
alkaline	B-GENE
phosphatases	I-GENE
and	O
5	B-GENE
-	I-GENE
nucleotidase	I-GENE


The	O
variable	O
HMG	B-GENE
dosage	O
regimen	O
was	O
found	O
to	O
offer	O
no	O
advantages	O
when	O
compared	O
with	O
our	O
standard	O
daily	O
dosage	O
regimen	O
.	O


By	O
contrast	O
,	O
secretory	B-GENE
HI	I-GENE
antibodies	I-GENE
were	O
not	O
demonstrated	O
at	O
the	O
onset	O
of	O
illness	O
in	O
any	O
of	O
the	O
patients	O
,	O
but	O
their	O
formation	O
started	O
early	O
and	O
the	O
antibodies	O
reached	O
maximal	O
levels	O
about	O
10	O
days	O
after	O
onset	O
of	O
illness	O
.	O


SGPT	B-GENE
,	O
SGOT	B-GENE
,	O
and	O
alkaline	B-GENE
phosphatase	I-GENE
concentrations	O
were	O
essentially	O
normal	O
in	O
all	O
subjects	O
.	O


Gamma	B-GENE
glutamyl	I-GENE
transpeptidase	I-GENE
(	O
GGTP	B-GENE
)	O
activity	O
in	O
the	O
seminal	O
fluid	O


An	O
IgG	B-GENE
monoclonal	O
gammopathy	O
was	O
present	O
in	O
the	O
serum	O
of	O
4	O
patients	O
and	O
Bence	O
-	O
Joanes	O
proteinuria	O
was	O
found	O
in	O
1	O
patient	O
.	O


Peroxydase	B-GENE
reaction	O
stains	O
were	O
negative	O
,	O
chloroacetate	B-GENE
esterase	I-GENE
were	O
strongly	O
positive	O
.	O


A	O
mixture	O
of	O
human	B-GENE
albumin	I-GENE
5	O
%	O
and	O
hydroxy	O
-	O
ethyl	O
-	O
starch	O
was	O
used	O
as	O
a	O
solution	O
for	O
dilution	O
.	O


Albumin	B-GENE
and	O
cyclic	O
AMP	O
levels	O
in	O
peritoneal	O
fluids	O
in	O
the	O
child	O


The	O
concentration	O
of	O
alpha	B-GENE
2	I-GENE
-	I-GENE
macroglobulin	I-GENE
,	O
alpha	B-GENE
1	I-GENE
-	I-GENE
antitrypsin	I-GENE
,	O
plasminogen	B-GENE
,	O
C3	B-GENE
-	I-GENE
complement	I-GENE
,	O
fibrinogen	B-GENE
degradation	I-GENE
products	I-GENE
(	O
FDP	B-GENE
)	O
and	O
fibrinolytic	O
activity	O
,	O
were	O
studied	O
in	O
the	O
aqueous	O
humour	O
and	O
serum	O
from	O
nine	O
patients	O
with	O
Fuchs	O
'	O
endothelial	O
dystrophy	O
,	O
17	O
patients	O
with	O
uncomplicated	O
senile	O
cataract	O
and	O
in	O
the	O
secondary	O
aqueous	O
from	O
six	O
cataract	O
patients	O
.	O


The	O
effect	O
of	O
CBZ	O
and	O
DPH	O
can	O
be	O
explained	O
by	O
interference	O
with	O
thyroid	O
hormone	O
binding	O
to	O
TBG	B-GENE
combined	O
with	O
enzyme	O
-	O
induced	O
increased	O
metabolic	O
clearance	O
rate	O
of	O
thyroid	O
hormones	O
without	O
homeostatic	O
maintenance	O
of	O
premedication	O
levels	O
of	O
FT4	O
and	O
FT3	O
.	O


Native	O
human	B-GENE
fibrinogen	I-GENE
was	O
brought	O
to	O
coagulation	O
by	O
adding	O
thrombin	B-GENE
.	O


The	O
Southern	O
technique	O
allowed	O
a	O
further	O
localization	O
of	O
the	O
region	O
of	O
most	O
extensive	O
transcription	O
to	O
a	O
1	O
.	O
8	O
kb	O
HindIII	B-GENE
-	O
EcoRI	B-GENE
fragment	O
.	O


There	O
was	O
no	O
correlation	O
between	O
serum	B-GENE
LH	I-GENE
and	O
chronological	O
or	O
bone	O
age	O
in	O
this	O
age	O
group	O
,	O
which	O
suggests	O
that	O
the	O
correlation	O
found	O
is	O
not	O
due	O
to	O
age	O
-	O
related	O
parallel	O
phenomena	O
.	O


Effect	O
of	O
succimer	O
on	O
the	O
intensity	O
of	O
tricarboxylic	B-GENE
acid	I-GENE
dehydrogenase	I-GENE
reactions	O
in	O
the	O
brain	O
of	O
rats	O
poisoned	O
with	O
mercuric	O
chloride	O


Total	O
VO2	O
was	O
decreased	O
in	O
both	O
groups	O
during	O
severe	O
hypoxia	O
but	O
limb	O
VO2	O
was	O
maintained	O
in	O
the	O
beta	O
-	O
block	O
group	O
.	O
beta	O
-	O
Block	O
prevented	O
the	O
fall	O
in	O
total	O
and	O
limb	O
peripheral	O
resistance	O
seen	O
in	O
severe	O
hypoxia	O
but	O
did	O
not	O
alter	O
the	O
consistently	O
more	O
efficient	O
utilization	O
of	O
total	O
O2	O
delivery	O
shown	O
by	O
the	O
limb	O
in	O
comparison	O
to	O
the	O
whole	O
body	O
by	O
higher	O
O2	O
extraction	O
ratios	O
and	O
lower	O
venous	O
O2	O
pressure	O
.	O
beta	B-GENE
-	I-GENE
Vasodilator	I-GENE
receptors	I-GENE
evidently	O
played	O
an	O
active	O
part	O
in	O
the	O
vasodilatation	O
seen	O
during	O
severe	O
hypoxia	O
.	O


Modulation	O
of	O
25	B-GENE
-	I-GENE
hydroxyvitamin	I-GENE
D3	I-GENE
-	I-GENE
24	I-GENE
-	I-GENE
hydroxylase	I-GENE
by	O
aminophylline	O
:	O
a	O
cytochrome	B-GENE
P	I-GENE
-	I-GENE
450	I-GENE
monooxygenase	I-GENE
system	O
.	O


Serum	B-GENE
ACTH	I-GENE
did	O
not	O
respond	O
to	O
insulin	B-GENE
and	O
metyrapone	O
.	O


Dopamine	B-GENE
receptor	I-GENE
blockade	O
and	O
the	O
neuroleptics	O
,	O
a	O
crystallographic	O
study	O
.	O


Similarly	O
,	O
maternal	B-GENE
serum	I-GENE
somatomedin	I-GENE
A	I-GENE
was	O
significantly	O
reduced	O
in	O
rats	O
nursing	O
large	O
litters	O
.	O


High	O
levels	O
of	O
serum	O
calcitonin	B-GENE
were	O
found	O
in	O
patients	O
with	O
chronic	O
renal	O
failure	O
.	O


Detection	O
of	O
anti	O
-	O
lymphocyte	O
antibodies	O
using	O
the	O
immunoperoxidase	B-GENE
antiglobulin	B-GENE
technic	O
.	O


Disrupted	O
vaccines	O
and	O
whole	O
-	O
virus	O
vaccines	O
containing	O
type	B-GENE
B	I-GENE
antigen	I-GENE
only	O
did	O
not	O
cause	O
significant	O
reactivity	O
.	O


Follow	O
-	O
up	O
controls	O
of	O
luteinizing	B-GENE
hormone	I-GENE
(	O
LH	B-GENE
)	O
,	O
follicle	B-GENE
stimulating	I-GENE
hormone	I-GENE
(	O
FSH	B-GENE
)	O
,	O
prolactin	B-GENE
(	O
HPRL	B-GENE
)	O
,	O
oestradiol	O
(	O
E2	O
)	O
,	O
progesterone	O
(	O
P	O
)	O
and	O
testosterone	O
(	O
T	O
)	O
in	O
the	O
catabolic	O
and	O
healing	O
phase	O
of	O
burn	O
disease	O
.	O


Renin	B-GENE
studies	O
performed	O
in	O
34	O
hypertensive	O
patients	O
and	O
in	O
a	O
control	O
group	O
of	O
11	O
recipients	O
showed	O
that	O
elevation	O
of	O
plasma	B-GENE
renin	I-GENE
activity	O
and	O
of	O
plasma	O
aldosterone	O
level	O
is	O
frequent	O
but	O
difficult	O
to	O
interpret	O
,	O
particularly	O
when	O
a	O
renal	O
artery	O
stenosis	O
is	O
observed	O
.	O


Thus	O
,	O
the	O
inhibition	O
of	O
pepsin	B-GENE
in	O
human	O
gastric	O
juice	O
does	O
not	O
appear	O
to	O
have	O
a	O
major	O
influence	O
on	O
the	O
healing	O
of	O
duodenal	O
ulcer	O
.	O


As	O
authorized	O
by	O
the	O
World	O
Health	O
Organization	O
29th	O
Expert	O
Committee	O
on	O
Biological	O
Standardization	O
,	O
the	O
preparation	O
of	O
human	B-GENE
prolactin	I-GENE
in	O
ampoules	O
coded	O
75	O
/	O
504	O
has	O
been	O
established	O
as	O
the	O
International	O
Reference	O
Preparation	O
(	O
IRP	O
)	O
of	O
human	B-GENE
prolactin	I-GENE
for	O
immunoassay	O
.	O


Such	O
marked	O
differences	O
are	O
found	O
occasionally	O
in	O
the	O
literature	O
:	O
heterophile	O
antibodies	O
against	O
bovine	B-GENE
gammaglobulin	I-GENE
are	O
regarded	O
as	O
responsible	O
for	O
the	O
interference	O
in	O
the	O
Sephadex	O
system	O
of	O
RIST	O
.	O


Serial	O
measurements	O
of	O
total	O
serum	O
IgE	B-GENE
appears	O
to	O
be	O
a	O
useful	O
index	O
of	O
disease	O
activity	O
in	O
ABPA	O
.	O


A	O
rise	O
of	O
hemoglobin	B-GENE
concentration	O
accompanied	O
by	O
an	O
increase	O
of	O
the	O
total	O
iron	O
in	O
the	O
blood	O
serum	O
of	O
white	O
mice	O
was	O
found	O
under	O
oxygen	O
pressure	O
of	O
4	O
atm	O
for	O
an	O
hour	O
(	O
preconvulsive	O
state	O
)	O
and	O
6	O
atm	O
(	O
convulsive	O
state	O
)	O
.	O


It	O
is	O
concluded	O
that	O
opiate	B-GENE
receptors	I-GENE
bordering	O
the	O
fourth	O
cerebral	O
ventricle	O
mediate	O
the	O
cardiovascular	O
and	O
hypnotic	O
action	O
of	O
fentanyl	O
.	O


Urinary	O
excretion	O
of	O
oestrone	O
,	O
oestradiol	O
-	O
17	O
beta	O
and	O
oestriol	O
in	O
pregnancies	O
complicated	O
by	O
steroid	B-GENE
sulphatase	I-GENE
deficiency	O
.	O


On	O
the	O
role	O
of	O
transferrin	B-GENE
in	O
the	O
uptake	O
of	O
gallium	O
by	O
tumor	O
cells	O
.	O


Screening	O
of	O
asthma	O
patients	O
by	O
determination	O
of	O
IgE	B-GENE
and	O
by	O
comprehension	O
of	O
spectrum	O
of	O
allergospecific	B-GENE
IgE	I-GENE
antibodies	I-GENE


A	O
highly	O
significant	O
correlation	O
was	O
found	O
between	O
the	O
presence	O
of	O
fibrinolytic	O
degradation	O
products	O
(	O
FDP	O
)	O
and	O
the	O
incidence	O
of	O
nephropathy	O
and	O
renal	O
insufficiency	O
,	O
as	O
well	O
as	O
between	O
the	O
presence	O
of	O
fibrin	B-GENE
monomers	I-GENE
(	O
Godal	O
'	O
s	O
ethanol	O
-	O
gelification	O
test	O
)	O
and	O
the	O
evolutive	O
signs	O
of	O
the	O
primary	O
disease	O
(	O
fever	O
,	O
accelerated	O
ESR	O
)	O
.	O


Serum	O
levels	O
of	O
IgG	B-GENE
and	O
IgM	B-GENE
were	O
also	O
raised	O
,	O
but	O
contrary	O
to	O
the	O
findings	O
of	O
other	O
observers	O
IgA	B-GENE
levels	O
were	O
normal	O
.	O


A	O
decrease	O
of	O
the	O
lysozyme	B-GENE
activity	O
coincided	O
with	O
the	O
clinical	O
improvement	O
of	O
the	O
bacterial	O
meningitis	O
.	O


The	O
multiple	O
factors	O
affecting	O
plasma	O
renin	B-GENE
activity	O
in	O
essential	O
hypertension	O
.	O


Prevention	O
of	O
acute	O
paraquat	O
toxicity	O
in	O
rats	O
by	O
superoxide	B-GENE
dismutase	I-GENE
.	O


The	O
effect	O
of	O
pure	O
natural	O
porcine	B-GENE
secretin	I-GENE
on	O
endocrine	O
and	O
exocrine	O
pancreatic	O
secretion	O
was	O
studied	O
in	O
the	O
totally	O
isolated	O
perfused	O
porcine	O
pancreas	O
.	O


In	O
biopsies	O
CK	B-GENE
-	I-GENE
MB	I-GENE
fraction	O
of	O
total	O
myocardial	O
CPK	B-GENE
was	O
37	O
%	O
,	O
the	O
total	B-GENE
-	I-GENE
CPK	I-GENE
activity	O
of	O
human	O
skeletal	O
muscles	O
still	O
shows	O
a	O
5	O
%	O
fraction	O
of	O
CK	B-GENE
-	I-GENE
MB	I-GENE
.	O


It	O
was	O
postulated	O
that	O
persistent	O
challenge	O
by	O
M	O
.	O
leprae	O
or	O
its	O
antigens	O
to	O
the	O
IgA	B-GENE
immunocytes	O
of	O
the	O
intestinal	O
epithelium	O
might	O
have	O
induced	O
tolerance	O
leading	O
to	O
IgA	B-GENE
deficiency	O
and	O
subsequent	O
subtotal	O
atrophy	O
of	O
the	O
intestinal	O
villi	O
in	O
the	O
patients	O
with	O
lepromatous	O
leprosy	O
.	O


Platelet	O
serotonin	O
(	O
5	O
-	O
HT	O
)	O
and	O
5	B-GENE
-	I-GENE
HT	I-GENE
releasing	I-GENE
factor	I-GENE
in	O
plasma	O
of	O
migrainous	O
patients	O
.	O


Carcinoembryonic	B-GENE
antigen	I-GENE
(	O
CEA	B-GENE
)	O
procedures	O
and	O
clinical	O
evaluation	O
.	O


Rheumatoid	B-GENE
factor	I-GENE
and	O
antinuclear	O
antibody	O
tests	O
were	O
frequently	O
positive	O
,	O
and	O
reactions	O
to	O
gold	O
therapy	O
were	O
more	O
frequent	O
than	O
in	O
other	O
rheumatoid	O
populations	O
.	O


Recurrence	O
of	O
bladder	O
tumors	O
among	O
the	O
original	O
9	O
cases	O
has	O
occurred	O
only	O
among	O
the	O
5	O
whose	O
properdin	B-GENE
levels	O
remained	O
below	O
the	O
median	O
.	O


Serum	B-GENE
amylase	I-GENE
became	O
markedly	O
elevated	O
(	O
2	O
,	O
624	O
CU	O
/	O
100	O
ml	O
)	O
,	O
as	O
did	O
the	O
serum	O
FFA	O
(	O
29	O
.	O
19	O
mEq	O
/	O
liter	O
)	O
.	O


The	O
sera	O
and	O
nasal	O
secretions	O
of	O
142	O
patients	O
,	O
who	O
were	O
positive	O
in	O
HD	O
or	O
mites	O
skin	O
test	O
,	O
were	O
subjected	O
to	O
a	O
radioallergosorbent	O
test	O
(	O
RAST	O
)	O
for	O
estimating	O
the	O
specific	O
IgE	B-GENE
antibody	I-GENE
activity	O
to	O
mites	O
.	O


The	O
prevalence	O
of	O
hepatitis	B-GENE
B	I-GENE
surface	I-GENE
antigen	I-GENE
(	O
HBsAg	B-GENE
)	O
and	O
anti	B-GENE
-	I-GENE
HBs	I-GENE
was	O
determined	O
by	O
a	O
sensitive	O
double	O
-	O
antibody	O
radio	O
-	O
immunoassay	O
technique	O
in	O
a	O
series	O
of	O
patients	O
with	O
chronic	O
liver	O
diseases	O
.	O


These	O
data	O
suggest	O
that	O
spontaneous	O
recovery	O
of	O
central	O
respiratory	O
function	O
after	O
intoxication	O
with	O
Soman	O
or	O
Sarin	O
may	O
not	O
be	O
related	O
to	O
the	O
return	O
of	O
AChE	B-GENE
activity	O
.	O


Pregnant	O
women	O
at	O
term	O
had	O
the	O
lowest	O
levels	O
of	O
antithrombin	B-GENE
III	I-GENE
.	O


Mean	O
corpuscular	B-GENE
hemoglobin	I-GENE
concentrations	O
remained	O
normal	O
for	O
48	O
h	O
and	O
then	O
decreased	O
in	O
both	O
groups	O
,	O
the	O
CO2	O
group	O
showing	O
the	O
larger	O
decrease	O
.	O


The	O
effect	O
of	O
calcitonin	B-GENE
,	O
a	O
large	O
amount	O
of	O
calcium	O
given	O
orally	O
,	O
pentagastrin	O
and	O
glucagon	B-GENE
on	O
plasma	O
47Ca	O
radioactivity	O
curves	O
in	O
subjects	O
pretreated	O
with	O
47Ca	O
was	O
examined	O
.	O


Effect	O
of	O
trauma	O
on	O
plasma	B-GENE
glucagon	I-GENE
and	O
insulin	B-GENE
concentrations	O
in	O
sheep	O
.	O


The	O
influence	O
of	O
adrenergic	O
nerves	O
of	O
the	O
response	O
of	O
blood	O
vessels	O
in	O
the	O
rabbit	O
ear	O
to	O
2	B-GENE
-	I-GENE
-	I-GENE
phenylalanine	I-GENE
-	I-GENE
8	I-GENE
-	I-GENE
lysine	I-GENE
vasopressin	I-GENE
(	O
Octapressin	B-GENE
)	O
.	O


The	O
second	O
and	O
third	O
responded	O
similarly	O
to	O
either	O
a	O
combined	O
cyclophosphamide	O
+	O
antilymphocyte	B-GENE
globulin	I-GENE
(	O
ALG	B-GENE
)	O
treatment	O
or	O
to	O
ALG	B-GENE
administration	O
preceded	O
by	O
a	O
small	O
dosage	O
of	O
cyclophosphamide	O
,	O
which	O
had	O
proved	O
ineffective	O
when	O
administered	O
alone	O
.	O


Alpha	B-GENE
-	I-GENE
1	I-GENE
antitrypsin	I-GENE
and	O
Indian	O
childhood	O
cirrhosis	O
.	O


There	O
was	O
a	O
slight	O
increase	O
in	O
total	O
transferrin	B-GENE
2	O
hr	O
after	O
1	O
tablet	O
and	O
values	O
remained	O
high	O
throughout	O
the	O
experiment	O
.	O


Thromboplastin	B-GENE
time	O
,	O
partial	O
thromboplastin	B-GENE
time	O
,	O
thrombin	B-GENE
time	O
,	O
heat	O
-	O
dependent	O
fibrin	B-GENE
,	O
clot	O
retraction	O
,	O
and	O
clotting	B-GENE
factors	I-GENE
II	I-GENE
,	I-GENE
V	I-GENE
,	I-GENE
VIII	I-GENE
,	I-GENE
IX	I-GENE
,	I-GENE
X	I-GENE
,	O
and	O
the	O
platelet	O
count	O
were	O
determined	O
.	O


Glucose	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
(	O
G	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
PD	I-GENE
)	O
deficiency	O
in	O
the	O
newborn	O
.	O


The	O
appearance	O
of	O
dyskinetic	O
movement	O
disorders	O
in	O
humans	O
following	O
the	O
chronic	O
use	O
of	O
levodopa	O
or	O
amphetamine	O
may	O
be	O
a	O
manifestation	O
of	O
similarly	O
increased	O
dopamine	B-GENE
receptor	I-GENE
site	I-GENE
sensitivity	O
within	O
the	O
striatum	O
.	O


Three	O
groups	O
of	O
patients	O
who	O
had	O
undergone	O
subtotal	O
thyroidectomy	O
for	O
Graves	O
'	O
s	O
disease	O
,	O
toxic	O
multinodular	O
goitre	O
,	O
or	O
euthyroid	O
multinodular	O
goitre	O
12	O
to	O
15	O
years	O
before	O
and	O
in	O
whom	O
a	O
normal	O
serum	O
thyroxine	O
(	O
T	O
-	O
4	O
)	O
level	O
was	O
found	O
were	O
each	O
divided	O
into	O
two	O
subgroups	O
on	O
the	O
basis	O
of	O
a	O
normal	O
or	O
a	O
raised	O
serum	O
thyrotrophin	B-GENE
concentration	O
.	O


Generally	O
,	O
a	O
correlation	O
was	O
observed	O
between	O
highest	O
concentrations	O
of	O
CSF	B-GENE
immunoglobulins	I-GENE
and	O
degree	O
of	O
meningeal	O
inflammatory	O
response	O
,	O
even	O
if	O
this	O
was	O
a	O
component	O
of	O
other	O
neurological	O
diseases	O
.	O


3	O
activities	O
of	O
the	O
factor	B-GENE
II	I-GENE
molecule	O
in	O
the	O
newborn	O
infant	O
at	O
term	O


One	O
site	O
,	O
PAL	B-GENE
,	O
occurs	O
within	O
the	O
10	O
bp	O
sequence	O
GGGGAGGAGG	O
.	O


To	O
determine	O
if	O
the	O
NF	B-GENE
(	I-GENE
H	I-GENE
)	I-GENE
promoter	I-GENE
can	O
be	O
activated	O
in	O
a	O
tissue	O
specific	O
manner	O
during	O
development	O
transgenic	O
mice	O
containing	O
the	O
promoter	O
region	O
linked	O
to	O
a	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
reporter	I-GENE
gene	I-GENE
were	O
generated	O
.	O


The	O
apparent	O
Kd	O
of	O
the	O
MetRS	B-GENE
/	I-GENE
CAU	I-GENE
operator	I-GENE
complex	I-GENE
is	O
one	O
order	O
magnitude	O
higher	O
than	O
that	O
of	O
the	O
ThrRS	B-GENE
/	I-GENE
CGU	I-GENE
operator	I-GENE
complex	I-GENE
.	O


Characterization	O
of	O
the	O
human	B-GENE
gene	I-GENE
encoding	I-GENE
cytokeratin	I-GENE
17	I-GENE
and	O
its	O
expression	O
pattern	O
.	O


A	O
statistically	O
significant	O
improvement	O
due	O
to	O
the	O
administration	O
of	O
Bromergon	O
was	O
observed	O
in	O
symptoms	O
associated	O
with	O
overreactiveness	O
to	O
normal	O
prolactin	B-GENE
levels	O
,	O
i	O
.	O
e	O
.	O
abdominal	O
tension	O
,	O
edema	O
,	O
weight	O
gain	O
and	O
breast	O
tenderness	O
.	O


In	O
7	O
of	O
9	O
cases	O
,	O
the	O
enhancer	O
is	O
fused	O
to	O
the	O
c	B-GENE
-	I-GENE
myc	I-GENE
bearing	I-GENE
sequences	I-GENE
of	O
chromosome	O
8	O
.	O


These	O
studies	O
show	O
that	O
UCRBP	B-GENE
binds	O
to	O
various	O
target	O
motifs	O
that	O
are	O
distinct	O
from	O
the	O
UCR	O
motif	O
:	O
the	O
adeno	B-GENE
-	I-GENE
associated	I-GENE
virus	I-GENE
P5	I-GENE
promoter	I-GENE
and	O
elements	O
in	O
the	O
immunoglobulin	B-GENE
light	I-GENE
-	I-GENE
and	I-GENE
heavy	I-GENE
-	I-GENE
chain	I-GENE
genes	O
,	O
as	O
well	O
as	O
elements	O
in	O
ribosomal	B-GENE
protein	I-GENE
genes	I-GENE
.	O


These	O
results	O
indicate	O
that	O
both	O
N	O
-	O
and	O
C	O
-	O
terminal	O
mutations	O
are	O
required	O
to	O
inhibit	O
transrepression	O
by	O
FBR	B-GENE
protein	I-GENE
and	O
that	O
multiple	O
structural	O
mutations	O
accompanied	O
by	O
posttranslational	O
protein	O
modification	O
alter	O
gene	O
regulation	O
by	O
FBR	B-GENE
protein	I-GENE
.	O


The	O
predicted	O
receptor	O
structure	O
includes	O
a	O
cysteine	O
-	O
rich	O
extracellular	O
domain	O
,	O
a	O
single	O
hydrophobic	O
transmembrane	O
domain	O
,	O
and	O
a	O
predicted	O
cytoplasmic	B-GENE
serine	I-GENE
/	I-GENE
threonine	I-GENE
kinase	I-GENE
domain	I-GENE
.	O


Analysis	O
of	O
the	O
entire	O
16	O
.	O
7	O
-	O
kb	O
mt	O
genome	O
determined	O
that	O
a	O
MDP1	B-GENE
mediates	O
cleavage	O
of	O
chick	O
mtDNA	O
in	O
vitro	O
at	O
three	O
H	O
-	O
and	O
two	O
L	O
-	O
strand	O
sequence	O
-	O
specific	O
target	O
sites	O
located	O
within	O
a	O
90	O
-	O
bp	O
A	O
+	O
T	O
-	O
rich	O
genomic	O
tract	O
,	O
theoretically	O
capable	O
of	O
forming	O
stable	O
secondary	O
structures	O
,	O
approximately	O
200	O
bases	O
upstream	O
from	O
the	O
H	O
-	O
strand	O
origin	O
(	O
OH	O
)	O
of	O
replication	O
.	O


A	O
rather	O
similar	O
pattern	O
of	O
results	O
was	O
obtained	O
with	O
respect	O
to	O
LMP2B	B-GENE
mRNA	I-GENE
expression	O
,	O
such	O
transcripts	O
being	O
detectable	O
only	O
in	O
a	O
subset	O
of	O
tumors	O
,	O
and	O
then	O
at	O
apparently	O
low	O
levels	O
.	O


Myogenic	O
differentiation	O
can	O
be	O
inhibited	O
by	O
the	O
adenovirus	O
E1a	B-GENE
protein	I-GENE
in	O
the	O
rat	O
L6	O
muscle	O
cell	O
line	O
.	O


The	O
DNA	O
sequence	O
of	O
the	O
sulfate	B-GENE
activation	I-GENE
locus	I-GENE
from	O
Escherichia	O
coli	O
K	O
-	O
12	O
has	O
been	O
determined	O
.	O


These	O
results	O
indicate	O
that	O
an	O
internal	O
short	O
element	O
located	O
at	O
the	O
very	O
5	O
'	O
terminal	O
of	O
L1	B-GENE
sequence	I-GENE
and	O
the	O
nuclear	O
factor	O
binding	O
to	O
the	O
element	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transcription	O
of	O
human	B-GENE
L1	I-GENE
.	O


Tumor	O
cells	O
were	O
focally	O
immunoreactive	O
for	O
neuron	B-GENE
-	I-GENE
specific	I-GENE
enolase	I-GENE
,	O
insulin	B-GENE
,	O
glucagon	B-GENE
and	O
VIP	B-GENE
.	O


To	O
define	O
the	O
number	O
and	O
nature	O
of	O
the	O
E6	B-GENE
and	O
E7	B-GENE
gene	I-GENE
products	O
expressed	O
in	O
BPV	O
-	O
1	O
-	O
transformed	O
cells	O
,	O
we	O
performed	O
immunoprecipitation	O
experiments	O
with	O
antisera	O
raised	O
to	O
bacterially	O
expressed	O
BPV	B-GENE
-	I-GENE
1	I-GENE
E6	I-GENE
and	O
E7	B-GENE
fusion	I-GENE
proteins	I-GENE
.	O


A	O
third	O
prominent	O
component	O
of	O
apparent	O
molecular	O
mass	O
16	O
kDa	O
displayed	O
several	O
properties	O
,	O
including	O
ability	O
to	O
bind	O
45Ca2	O
+	O
,	O
that	O
are	O
characteristic	O
of	O
the	O
regulatory	O
(	O
B	O
)	O
subunit	O
of	O
mammalian	B-GENE
calcineurin	I-GENE
and	O
was	O
recognized	O
by	O
an	O
antiserum	O
raised	O
against	O
bovine	B-GENE
calcineurin	I-GENE
.	O


As	O
was	O
observed	O
previously	O
for	O
MATa	B-GENE
cna1	B-GENE
cna2	B-GENE
double	O
mutants	O
,	O
MATa	B-GENE
cnb1	B-GENE
mutants	I-GENE
were	O
defective	O
in	O
their	O
ability	O
to	O
recover	O
from	O
alpha	B-GENE
-	I-GENE
factor	I-GENE
-	O
induced	O
growth	O
arrest	O
.	O


A	O
position	O
-	O
independent	O
activation	O
domain	O
which	O
contained	O
conserved	O
regions	O
II	O
and	O
III	O
was	O
identified	O
at	O
the	O
carboxyl	O
terminus	O
of	O
the	O
HNF	B-GENE
-	I-GENE
3	I-GENE
beta	I-GENE
protein	I-GENE
(	O
amino	O
acids	O
361	O
to	O
458	O
)	O
.	O


HNF	B-GENE
-	I-GENE
3	I-GENE
beta	I-GENE
amino	I-GENE
-	I-GENE
terminal	I-GENE
sequences	I-GENE
defined	O
by	O
conserved	O
region	O
IV	O
also	O
contributed	O
to	O
transactivation	O
,	O
but	O
region	O
IV	O
activity	O
required	O
the	O
participation	O
of	O
the	O
region	O
II	O
-	O
III	O
domain	O
.	O


Nocodazole	O
arrest	O
of	O
DU249	O
cells	O
was	O
exploited	O
for	O
the	O
detection	O
of	O
an	O
M	O
-	O
phase	O
-	O
activated	O
MBP	B-GENE
kinase	I-GENE
that	O
was	O
resolved	O
from	O
p41	B-GENE
MAP	I-GENE
kinase	I-GENE
by	O
phenyl	O
-	O
Superose	O
chromatography	O
.	O


The	O
319	O
base	O
pair	O
region	O
immediately	O
upstream	O
of	O
the	O
CAP	O
site	O
is	O
characterized	O
by	O
the	O
lack	O
of	O
a	O
proximal	O
TATA	O
box	O
and	O
the	O
presence	O
of	O
sequences	O
similar	O
to	O
GC	O
boxes	O
,	O
CACCC	O
boxes	O
,	O
CCAAT	O
boxes	O
,	O
activator	B-GENE
protein	I-GENE
2	I-GENE
(	O
Ap	B-GENE
-	I-GENE
2	I-GENE
)	O
sites	O
,	O
partial	O
glucocorticoid	O
response	O
elements	O
(	O
GREs	O
)	O
,	O
and	O
partial	O
cyclic	O
AMP	O
response	O
elements	O
(	O
CREs	O
)	O
.	O


Insertional	O
inactivation	O
of	O
sms	B-GENE
led	O
to	O
increased	O
sensitivity	O
to	O
the	O
alkylating	O
agent	O
methylmethane	O
sulfonate	O
,	O
but	O
not	O
to	O
a	O
requirement	O
for	O
serine	O
or	O
other	O
metabolites	O
.	O


NSCL	B-GENE
-	I-GENE
1	I-GENE
is	O
expressed	O
in	O
a	O
larger	O
number	O
of	O
these	O
cell	O
lines	O
.	O


Truncation	O
variants	O
of	O
peptides	O
isolated	O
from	O
MHC	B-GENE
class	I-GENE
II	I-GENE
molecules	I-GENE
suggest	O
sequence	O
motifs	O
.	O


Intermediate	O
levels	O
of	O
gene	O
activity	O
were	O
observed	O
for	O
TnI	B-GENE
enhancers	I-GENE
containing	O
E	O
-	O
boxes	O
derived	O
from	O
the	O
MCK	B-GENE
left	I-GENE
E	I-GENE
-	I-GENE
box	I-GENE
site	I-GENE
or	O
from	O
the	O
Ig	B-GENE
kappa	I-GENE
E2	I-GENE
E	I-GENE
-	I-GENE
box	I-GENE
.	O


The	O
CANNTG	O
motifs	O
were	O
found	O
to	O
bind	O
MyoD	B-GENE
and	O
myogenin	B-GENE
fusion	I-GENE
proteins	I-GENE
and	O
to	O
interact	O
with	O
proteins	O
in	O
nuclear	O
extracts	O
from	O
cultured	O
myotubes	O
.	O


The	O
structure	O
of	O
the	O
calcineurin	B-GENE
A	I-GENE
gene	I-GENE
was	O
determined	O
by	O
comparison	O
of	O
the	O
genomic	O
and	O
cDNA	O
sequences	O
.	O


The	O
basal	O
promoter	O
elements	O
of	O
murine	B-GENE
cytochrome	I-GENE
c	I-GENE
oxidase	I-GENE
subunit	I-GENE
IV	I-GENE
gene	I-GENE
consist	O
of	O
tandemly	O
duplicated	O
ets	B-GENE
motifs	O
that	O
bind	O
to	O
GABP	B-GENE
-	I-GENE
related	I-GENE
transcription	I-GENE
factors	I-GENE
.	O


Mapping	O
the	O
cAMP	B-GENE
receptor	I-GENE
protein	I-GENE
contact	I-GENE
site	I-GENE
on	O
the	O
alpha	O
subunit	O
of	O
Escherichia	B-GENE
coli	I-GENE
RNA	I-GENE
polymerase	I-GENE
.	O


A	O
major	O
mechanism	O
whereby	O
steroid	B-GENE
hydroxylase	I-GENE
gene	I-GENE
transcription	O
is	O
regulated	O
in	O
the	O
adrenal	O
cortex	O
requires	O
the	O
pituitary	O
peptide	O
hormone	O
,	O
ACTH	B-GENE
,	O
which	O
acts	O
via	O
cAMP	O
.	O


Km	O
and	O
Vmax	O
for	O
two	O
substrates	O
,	O
src	B-GENE
-	I-GENE
related	I-GENE
peptide	I-GENE
and	O
poly	O
(	O
Glu	O
,	O
Tyr	O
)	O
(	O
4	O
:	O
1	O
)	O
,	O
were	O
2	O
.	O
4	O
mM	O
and	O
2	O
.	O
5	O
mumol	O
min	O
-	O
1	O
mg	O
-	O
1	O
and	O
0	O
.	O
26	O
mM	O
and	O
1	O
.	O
2	O
mumol	O
min	O
-	O
1	O
mg	O
-	O
1	O
,	O
respectively	O
.	O


We	O
have	O
cloned	O
and	O
characterized	O
a	O
55	O
-	O
kb	O
region	O
of	O
DNA	O
surrounding	O
HRAS1	B-GENE
.	O


Characterization	O
of	O
the	O
regulon	O
controlled	O
by	O
the	O
leucine	B-GENE
-	I-GENE
responsive	I-GENE
regulatory	I-GENE
protein	I-GENE
in	O
Escherichia	O
coli	O
.	O


This	O
mutation	O
also	O
results	O
in	O
markedly	O
decreased	O
levels	O
of	O
CAD	B-GENE
mRNA	I-GENE
and	O
protein	O
in	O
the	O
mutant	O
.	O


Mutational	O
studies	O
revealed	O
that	O
it	O
was	O
the	O
homeodomain	B-GENE
binding	I-GENE
site	I-GENE
II	I-GENE
sequence	I-GENE
that	O
was	O
required	O
for	O
this	O
regulation	O
.	O


In	O
a	O
retrospective	O
analysis	O
of	O
data	O
from	O
35	O
cases	O
with	O
malignant	O
lymphoma	O
from	O
a	O
cohort	O
of	O
2017	O
HIV	O
-	O
infected	O
patients	O
,	O
the	O
stage	O
of	O
HIV	O
-	O
disease	O
,	O
the	O
CD4	B-GENE
counts	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
and	O
the	O
use	O
of	O
antineoplastic	O
agents	O
or	O
radiotherapy	O
were	O
correlated	O
with	O
outcome	O
.	O


Interaction	O
of	O
H	B-GENE
-	I-GENE
2Eb	I-GENE
with	O
an	O
IAP	B-GENE
retrotransposon	I-GENE
in	O
the	O
A20	O
/	O
2J	O
B	O
cell	O
lymphoma	O
.	O


The	O
subunit	O
protein	O
of	O
curli	B-GENE
was	O
highly	O
homologous	O
at	O
its	O
amino	O
terminus	O
to	O
SEF	B-GENE
-	I-GENE
17	I-GENE
,	O
the	O
subunit	O
protein	O
of	O
thin	O
,	O
aggregative	O
fimbriae	O
of	O
Salmonella	O
enteritidis	O
27655	O
strain	O
3b	O
,	O
suggesting	O
that	O
these	O
fibres	O
form	O
a	O
novel	O
class	O
of	O
surface	O
organelles	O
on	O
enterobacteria	O
.	O


Substitution	O
of	O
the	O
DR1	B-GENE
beta	I-GENE
chain	I-GENE
with	O
H	B-GENE
-	I-GENE
2E	I-GENE
beta	I-GENE
k	I-GENE
led	O
to	O
a	O
dramatic	O
loss	O
of	O
recognition	O
;	O
alpha	O
chain	O
substitution	O
had	O
a	O
less	O
marked	O
effect	O
.	O


From	O
August	O
1989	O
to	O
October	O
1990	O
,	O
83	O
pregnant	O
Chinese	O
women	O
were	O
the	O
subjects	O
for	O
measuring	O
the	O
levels	O
of	O
plasma	O
functional	O
antithrombin	B-GENE
III	I-GENE
(	O
AT	B-GENE
III	I-GENE
)	O
activity	O
.	O


Currents	O
aspects	O
of	O
H2	B-GENE
receptor	I-GENE
antagonists	O
in	O
the	O
treatment	O
of	O
ulcers	O


Differential	O
expression	O
of	O
the	O
"	O
B	O
"	O
subunit	O
of	O
the	O
vacuolar	B-GENE
H	I-GENE
(	I-GENE
+	I-GENE
)	I-GENE
-	I-GENE
ATPase	I-GENE
in	O
bovine	O
tissues	O
.	O


In	O
addition	O
,	O
the	O
hGCSFR	B-GENE
gene	I-GENE
was	O
chromosomally	O
localized	O
by	O
Southern	O
blot	O
analysis	O
of	O
its	O
segregation	O
pattern	O
in	O
a	O
panel	O
of	O
rodent	O
-	O
human	O
hybrid	O
DNAs	O
using	O
the	O
radiolabeled	O
cDNA	O
probe	O
.	O


These	O
exons	O
,	O
further	O
identified	O
as	O
exons	O
9	O
,	O
10	O
,	O
and	O
11	O
,	O
together	O
encode	O
the	O
37	O
amino	O
acid	O
residues	O
present	O
in	O
alpha	B-GENE
s1	I-GENE
-	I-GENE
casein	I-GENE
variant	I-GENE
A	I-GENE
but	O
missing	O
in	O
variant	O
F	O
.	O


Homodimers	O
of	O
the	O
three	O
proteins	O
specifically	O
recognize	O
the	O
G	O
-	O
box	O
motif	O
,	O
with	O
GBF1	B-GENE
and	O
GBF3	B-GENE
binding	O
symmetrically	O
to	O
this	O
palindromic	O
sequence	O
.	O


Genetic	O
and	O
biochemical	O
evidence	O
suggests	O
that	O
v	B-GENE
-	I-GENE
Crk	I-GENE
can	O
induce	O
transformation	O
of	O
chicken	O
embryo	O
fibroblasts	O
by	O
influencing	O
the	O
activity	O
of	O
cellular	O
proteins	O
involved	O
in	O
growth	O
regulation	O
.	O


In	O
addition	O
,	O
C	B-GENE
/	I-GENE
EBP	I-GENE
beta	I-GENE
and	O
C	B-GENE
/	I-GENE
EBP	I-GENE
gamma	I-GENE
readily	O
heterodimerize	O
with	O
each	O
other	O
as	O
well	O
as	O
with	O
C	B-GENE
/	I-GENE
EBP	I-GENE
alpha	I-GENE
.	O


Between	O
acoR	B-GENE
and	O
acoXABC	B-GENE
,	O
two	O
different	O
types	O
of	O
sequences	O
with	O
dual	O
rotational	O
symmetry	O
[	O
CAC	O
-	O
(	O
N11	O
to	O
N18	O
)	O
-	O
GTG	O
and	O
TGT	O
-	O
(	O
N10	O
to	O
N14	O
)	O
-	O
ACA	O
]	O
were	O
found	O
;	O
these	O
sequences	O
are	O
similar	O
to	O
NtrC	B-GENE
and	O
NifA	B-GENE
upstream	I-GENE
activator	I-GENE
sequences	I-GENE
,	O
respectively	O
.	O


Here	O
we	O
demonstrate	O
that	O
the	O
protein	O
product	O
of	O
the	O
ref	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
stimulates	O
the	O
DNA	O
binding	O
activity	O
of	O
Fos	B-GENE
-	O
Jun	B-GENE
heterodimers	O
,	O
Jun	B-GENE
-	O
Jun	B-GENE
homodimers	O
and	O
Hela	O
cell	O
AP	B-GENE
-	I-GENE
1	I-GENE
proteins	I-GENE
as	O
well	O
as	O
that	O
of	O
several	O
other	O
transcription	O
factors	O
including	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
,	O
Myb	B-GENE
and	O
members	O
of	O
the	O
ATF	B-GENE
/	O
CREB	B-GENE
family	O
.	O


We	O
analyzed	O
an	O
EBV	O
B	O
-	O
cell	O
clone	O
,	O
E29	O
.	O
1	O
,	O
derived	O
from	O
an	O
11	O
week	O
-	O
old	O
embryo	O
,	O
and	O
secreting	O
both	O
IgM	B-GENE
kappa	I-GENE
and	O
IgM	B-GENE
lambda	I-GENE
.	O


Through	O
Southern	O
blot	O
analyses	O
of	O
DNA	O
from	O
backcross	O
and	O
cogenic	O
mice	O
,	O
recombinant	O
inbred	O
strains	O
,	O
and	O
somatic	O
cell	O
hybrids	O
,	O
the	O
genetic	O
loci	O
that	O
produce	O
the	O
cyclin	B-GENE
B1	I-GENE
-	I-GENE
related	I-GENE
sequences	I-GENE
(	O
designated	O
loci	B-GENE
Cycb1	I-GENE
-	I-GENE
rs1	I-GENE
to	O
Cycb1	B-GENE
-	I-GENE
rs9	I-GENE
)	O
were	O
mapped	O
on	O
mouse	O
chromosomes	O
5	O
,	O
1	O
,	O
17	O
,	O
4	O
,	O
14	O
,	O
13	O
,	O
7	O
,	O
X	O
,	O
and	O
8	O
,	O
respectively	O
.	O


The	O
neurohypophysial	O
vasopressin	B-GENE
and	O
oxytocin	B-GENE
content	O
was	O
bioassayed	O
by	O
pressor	O
effect	O
following	O
Dekanski	O
or	O
milk	O
-	O
ejection	O
activity	O
in	O
vitro	O
following	O
van	O
Dongen	O
and	O
Hays	O
,	O
respectively	O
.	O


Urease	B-GENE
activity	O
,	O
judged	O
as	O
the	O
amount	O
of	O
ammonia	O
production	O
from	O
urea	O
,	O
could	O
be	O
measured	O
at	O
25	O
ng	O
per	O
tube	O
(	O
S	O
/	O
N	O
=	O
1	O
.	O
5	O
)	O
with	O
Jack	B-GENE
bean	I-GENE
meal	I-GENE
urease	I-GENE
.	O


Our	O
experiments	O
suggest	O
that	O
the	O
SCL	B-GENE
gene	I-GENE
can	O
be	O
a	O
target	O
for	O
the	O
erythroid	B-GENE
transcription	I-GENE
factor	I-GENE
GATA	I-GENE
-	I-GENE
1	I-GENE
and	O
that	O
the	O
SCL	B-GENE
gene	I-GENE
product	I-GENE
serves	O
as	O
a	O
positive	O
regulator	O
of	O
erythroid	O
differentiation	O
.	O


These	O
results	O
lead	O
us	O
to	O
hypothesize	O
that	O
a	O
single	O
multisubunit	B-GENE
TFIID	I-GENE
protein	I-GENE
supports	O
transcriptional	O
stimulation	O
by	O
diverse	O
activation	O
domains	O
and	O
from	O
a	O
TATA	O
-	O
less	O
promoter	O
.	O


Cleavage	O
by	O
the	O
intron	O
-	O
encoded	O
enzyme	O
(	O
I	B-GENE
-	I-GENE
CreI	I-GENE
)	O
occurs	O
5	O
bp	O
and	O
1	O
bp	O
3	O
'	O
to	O
the	O
intron	O
insertion	O
site	O
(	O
in	O
the	O
3	O
'	O
-	O
exon	O
)	O
in	O
the	O
top	O
(	O
/	O
)	O
and	O
bottom	O
(	O
,	O
)	O
strands	O
,	O
respectively	O
,	O
resulting	O
in	O
4	O
-	O
nt	O
single	O
-	O
stranded	O
overhangs	O
with	O
3	O
'	O
-	O
OH	O
termini	O
.	O


The	O
results	O
support	O
earlier	O
reports	O
that	O
collagenase	B-GENE
inhibitors	O
are	O
useful	O
in	O
controlling	O
blister	O
formation	O
in	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O


Western	O
blot	O
analyses	O
detect	O
anti	B-GENE
-	I-GENE
E	I-GENE
-	O
specific	O
immunoreactivity	O
in	O
affinity	O
-	O
purified	O
extracts	O
derived	O
from	O
the	O
bacterial	O
expression	O
of	O
a	O
truncated	B-GENE
AMPD3	I-GENE
cDNA	I-GENE
.	O


Behind	O
the	O
ATPase	B-GENE
cluster	I-GENE
,	O
two	O
open	O
reading	O
frames	O
were	O
detected	O
that	O
are	O
not	O
homologous	O
to	O
any	O
known	O
chloroplast	O
gene	O
.	O


Using	O
either	O
a	O
p50	B-GENE
-	O
or	O
p65	B-GENE
-	I-GENE
selected	I-GENE
kappa	I-GENE
B	I-GENE
motif	I-GENE
,	O
which	O
displayed	O
differential	O
binding	O
with	O
respect	O
to	O
the	O
other	O
protein	O
,	O
little	O
to	O
no	O
binding	O
was	O
observed	O
with	O
the	O
heterodimeric	B-GENE
NF	I-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
complex	I-GENE
.	O


However	O
,	O
a	O
cosmid	O
clone	O
containing	O
the	O
entire	O
mouse	B-GENE
alpha	I-GENE
1	I-GENE
(	I-GENE
I	I-GENE
)	I-GENE
gene	I-GENE
,	O
including	O
3	O
.	O
7	O
kb	O
of	O
5	O
'	O
-	O
and	O
4	O
kb	O
of	O
3	O
'	O
-	O
flanking	O
DNA	O
,	O
was	O
expressed	O
at	O
reduced	O
levels	O
in	O
fibroblasts	O
overexpressing	O
oncogenic	B-GENE
ras	I-GENE
.	O


By	O
screening	O
a	O
Y1	O
cell	O
cDNA	O
library	O
with	O
the	O
DNA	O
-	O
binding	O
region	O
of	O
the	O
H	B-GENE
-	I-GENE
2RIIBP	I-GENE
nuclear	I-GENE
hormone	I-GENE
receptor	I-GENE
cDNA	I-GENE
,	O
we	O
isolated	O
a	O
cDNA	O
that	O
is	O
selectively	O
expressed	O
in	O
steroidogenic	O
cells	O
.	O


By	O
using	O
lambda	O
gt11	O
expression	O
cloning	O
with	O
oligonucleotides	O
corresponding	O
to	O
the	O
human	O
immunodeficiency	O
virus	O
1	O
TATA	O
element	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
cellular	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
123	O
kDa	O
that	O
we	O
designate	O
TATA	B-GENE
element	I-GENE
modulatory	I-GENE
factor	I-GENE
(	O
TMF	B-GENE
)	O
.	O


Blood	O
levels	O
of	O
melatonin	O
,	O
serotonin	O
,	O
cortisol	O
,	O
and	O
prolactin	B-GENE
in	O
relation	O
to	O
the	O
circadian	O
rhythm	O
of	O
platelet	O
serotonin	O
uptake	O
.	O


The	O
TIMP	B-GENE
(	O
-	O
59	O
/	O
-	O
53	O
)	O
AP1	B-GENE
site	O
is	O
a	O
promiscuous	O
motif	O
that	O
binds	O
c	B-GENE
-	I-GENE
Fos	I-GENE
/	O
c	B-GENE
-	I-GENE
Jun	I-GENE
AP1	B-GENE
translated	O
in	O
vitro	O
and	O
is	O
an	O
effective	O
competitor	O
for	O
binding	O
of	O
nuclear	B-GENE
AP1	I-GENE
factors	I-GENE
to	O
the	O
consensus	O
TRE	O
,	O
but	O
in	O
addition	O
it	O
binds	O
factors	O
that	O
do	O
not	O
associate	O
with	O
the	O
consensus	O
TRE	O
.	O


Involvement	O
of	O
AP1	B-GENE
and	O
PEA3	B-GENE
binding	I-GENE
sites	I-GENE
in	O
the	O
regulation	O
of	O
murine	B-GENE
tissue	I-GENE
inhibitor	I-GENE
of	I-GENE
metalloproteinases	I-GENE
-	I-GENE
1	I-GENE
(	O
TIMP	B-GENE
-	I-GENE
1	I-GENE
)	O
transcription	O
.	O


A	O
controlled	O
trial	O
of	O
recombinant	B-GENE
human	I-GENE
granulocyte	I-GENE
-	I-GENE
macrophage	I-GENE
colony	I-GENE
-	I-GENE
stimulating	I-GENE
factor	I-GENE
after	O
total	O
body	O
irradiation	O
,	O
high	O
-	O
dose	O
chemotherapy	O
,	O
and	O
autologous	O
bone	O
marrow	O
transplantation	O
for	O
acute	O
lymphoblastic	O
leukemia	O
or	O
malignant	O
lymphoma	O
.	O


Examination	O
of	O
ANCA	B-GENE
is	O
not	O
only	O
a	O
significant	O
contribution	O
towards	O
a	O
more	O
accurate	O
diagnosis	O
of	O
renal	O
vasculitis	O
,	O
but	O
also	O
an	O
indicator	O
of	O
the	O
activity	O
of	O
the	O
disease	O
and	O
thus	O
of	O
the	O
effectiveness	O
of	O
immunosuppressive	O
treatment	O
.	O


The	O
distinguishing	O
features	O
involved	O
eight	O
amino	O
acid	O
changes	O
,	O
including	O
a	O
single	O
lysine	O
deletion	O
relative	O
to	O
a	O
primate	O
consensus	O
sequence	O
in	O
the	O
first	O
complementary	O
-	O
determing	O
region	O
of	O
V1J1	B-GENE
.	O


On	O
the	O
basis	O
of	O
these	O
unique	O
properties	O
,	O
the	O
newly	O
characterized	O
hemagglutinin	B-GENE
has	O
been	O
termed	O
Limulus	B-GENE
18K	I-GENE
agglutination	I-GENE
-	I-GENE
aggregation	I-GENE
factor	I-GENE
(	O
18K	B-GENE
-	I-GENE
LAF	I-GENE
)	O
.	O


The	O
shift	O
to	O
the	O
nonpermissive	O
temperature	O
is	O
accompanied	O
by	O
the	O
loss	O
of	O
guanyl	O
nucleotide	O
-	O
dependent	O
activity	O
of	O
adenylylcyclase	B-GENE
in	O
vitro	O
.	O


It	O
corresponds	O
to	O
the	O
complete	O
mitochondrial	O
presequence	O
and	O
the	O
lipoyl	O
-	O
bearing	O
domain	O
that	O
are	O
encoded	O
by	O
exons	O
I	O
through	O
IV	O
of	O
the	O
functional	O
E2	B-GENE
gene	I-GENE
.	O


According	O
to	O
out	O
field	O
research	O
,	O
the	O
tick	O
fauna	O
was	O
very	O
rich	O
throughout	O
that	O
area	O
,	O
and	O
it	O
was	O
permissible	O
enough	O
to	O
determine	O
ticks	O
as	O
the	O
vectors	O
,	O
based	O
on	O
arising	O
of	O
anti	B-GENE
-	I-GENE
SF	I-GENE
group	I-GENE
rickettsiae	I-GENE
(	O
SFGR	B-GENE
)	O
antibody	O
in	O
mice	O
inoculated	O
with	O
some	O
tick	O
emulsions	O
,	O
findings	O
of	O
rickettsiae	O
reactive	O
to	O
patient	O
sera	O
or	O
a	O
species	O
-	O
specific	O
monoclonal	O
antibody	O
to	O
JSFR	B-GENE
in	O
the	O
hemolymph	O
cells	O
of	O
some	O
ticks	O
,	O
and	O
electron	O
microscopical	O
observations	O
of	O
SFGR	B-GENE
in	O
various	O
internal	O
organs	O
including	O
the	O
salivary	O
gland	O
of	O
ticks	O
.	O


Nucleotide	O
sequence	O
and	O
transcriptional	O
analysis	O
of	O
the	O
polyhedrin	B-GENE
gene	I-GENE
of	O
Spodoptera	O
exigua	O
nuclear	O
polyhedrosis	O
virus	O
.	O


Subcutaneous	O
administration	O
of	O
the	O
somatostatin	B-GENE
analogue	O
,	O
octreotide	O
,	O
100	O
micrograms	O
thrice	O
daily	O
,	O
resulted	O
in	O
a	O
sustained	O
improvement	O
in	O
diarrhoea	O
and	O
disappearance	O
of	O
faecal	O
incontinence	O
without	O
reducing	O
calcitonin	B-GENE
levels	O
.	O


No	O
other	O
changes	O
in	O
hematopoietic	O
differentiation	O
status	O
were	O
observed	O
in	O
association	O
with	O
Id	B-GENE
-	I-GENE
SCL	I-GENE
expression	O
.	O


Purification	O
and	O
cloning	O
of	O
a	O
novel	O
serine	B-GENE
protease	I-GENE
,	O
RNK	B-GENE
-	I-GENE
Met	I-GENE
-	I-GENE
1	I-GENE
,	O
from	O
the	O
granules	O
of	O
a	O
rat	O
natural	O
killer	O
cell	O
leukemia	O
.	O


We	O
describe	O
here	O
17	O
dominant	B-GENE
GCN2	I-GENE
mutations	I-GENE
that	O
lead	O
to	O
derepression	O
of	O
GCN4	B-GENE
expression	O
in	O
the	O
absence	O
of	O
amino	O
acid	O
starvation	O
.	O


In	O
addition	O
,	O
the	O
utility	O
of	O
beta	B-GENE
2	I-GENE
transferrin	I-GENE
assay	O
in	O
the	O
diagnosis	O
of	O
cerebrospinal	O
fluid	O
otorrhea	O
is	O
presented	O
.	O


The	O
structural	O
genes	O
encoding	O
glyceraldehyde	B-GENE
-	I-GENE
3	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
(	O
GAPDH	B-GENE
)	O
,	O
3	B-GENE
-	I-GENE
phosphoglycerate	I-GENE
kinase	I-GENE
(	O
PGK	B-GENE
)	O
and	O
the	O
N	O
-	O
terminal	O
part	O
of	O
triosephosphate	B-GENE
isomerase	I-GENE
(	O
TIM	B-GENE
)	O
from	O
mesophilic	O
Bacillus	O
megaterium	O
DSM319	O
have	O
been	O
cloned	O
as	O
a	O
gene	O
cluster	O
(	O
gap	B-GENE
operon	I-GENE
)	O
by	O
complementation	O
of	O
an	O
Escherichia	O
coli	O
gap	B-GENE
amber	I-GENE
mutant	I-GENE
.	O


To	O
study	O
the	O
significance	O
of	O
these	O
domains	O
and	O
the	O
overall	O
evolutionary	O
conservation	O
of	O
the	O
gene	O
,	O
the	O
homolog	O
from	O
Drosophila	O
melanogaster	O
was	O
isolated	O
by	O
low	O
stringency	O
hybridizations	O
using	O
two	O
flanking	O
probes	O
of	O
the	O
human	B-GENE
ERCC3	I-GENE
cDNA	I-GENE
.	O


The	O
tramtrack	B-GENE
(	O
ttk	B-GENE
)	O
gene	O
of	O
Drosophila	O
encodes	O
69	O
-	O
kDa	O
and	O
88	O
-	O
kDa	O
proteins	O
through	O
alternative	O
splicing	O
of	O
the	O
primary	O
ttk	B-GENE
transcript	I-GENE
.	O


Removal	O
of	O
beta	B-GENE
2	I-GENE
-	I-GENE
microglobulin	I-GENE
by	O
hemodialysis	O
and	O
hemofiltration	O
:	O
a	O
four	O
year	O
follow	O
up	O
.	O


GAL4	B-GENE
-	O
VP16	B-GENE
-	O
mediated	O
antirepression	O
required	O
an	O
auxiliary	O
factor	O
,	O
denoted	O
as	O
a	O
co	O
-	O
antirepressor	O
,	O
which	O
was	O
partially	O
purified	O
from	O
Drosophila	O
embryos	O
.	O


Therefore	O
,	O
ICSBP	B-GENE
may	O
be	O
involved	O
in	O
maintaining	O
submaximal	O
transcriptional	O
activity	O
of	O
IFN	B-GENE
-	O
inducible	O
genes	O
in	O
hematopoietic	O
cells	O
.	O


These	O
results	O
indicate	O
a	O
possible	O
involvement	O
of	O
endogenous	O
opioid	O
peptides	O
in	O
the	O
cardiac	O
effects	O
due	O
to	O
myocardial	O
ischaemia	O
and	O
reperfusion	O
,	O
mediated	O
by	O
opiate	B-GENE
receptors	I-GENE
through	O
opiate	O
antagonism	O
.	O


Since	O
CENP	B-GENE
-	I-GENE
B	I-GENE
gene	I-GENE
is	O
conserved	O
in	O
mammalian	O
species	O
and	O
CENP	B-GENE
-	I-GENE
B	I-GENE
boxes	I-GENE
are	O
found	O
also	O
in	O
mouse	O
centromere	O
satellite	O
DNA	O
(	O
minor	O
satellite	O
)	O
,	O
this	O
sequence	O
-	O
specific	O
DNA	O
-	O
protein	O
interaction	O
may	O
be	O
important	O
for	O
some	O
kind	O
of	O
common	O
centromere	O
function	O
.	O


However	O
,	O
in	O
the	O
subgroup	O
with	O
normal	O
Ht	O
(	O
<	O
0	O
.	O
45	O
l	O
/	O
l	O
;	O
n	O
=	O
201	O
)	O
there	O
was	O
a	O
significant	O
reduction	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
the	O
mortality	O
after	O
3	O
months	O
(	O
27	O
%	O
and	O
16	O
%	O
,	O
respectively	O
)	O
and	O
an	O
increase	O
of	O
independence	O
at	O
home	O
(	O
35	O
%	O
and	O
48	O
%	O
,	O
respectively	O
)	O
due	O
to	O
a	O
reduction	O
of	O
the	O
viscosity	O
by	O
means	O
of	O
haemodilution	O
with	O
albumin	B-GENE
(	O
a	O
specific	O
viscosity	O
effect	O
in	O
the	O
normovolaemic	O
group	O
)	O
.	O


Assay	O
of	O
urea	O
by	O
immobilized	O
urease	B-GENE
coupled	O
to	O
a	O
differential	O
pH	O
-	O
meter	O
.	O


Therefore	O
,	O
the	O
molecular	O
mechanisms	O
of	O
the	O
estrogen	O
action	O
that	O
govern	O
the	O
lactoferrin	B-GENE
gene	I-GENE
expression	O
differ	O
between	O
mouse	O
and	O
human	O
.	O


Four	O
short	O
nucleotide	O
sequences	O
(	O
boxes	O
I	O
to	O
IV	O
)	O
contribute	O
to	O
the	O
light	O
responsiveness	O
of	O
the	O
parsley	B-GENE
chalcone	I-GENE
synthase	I-GENE
promoter	I-GENE
.	O


Exposure	O
to	O
hepatitis	O
B	O
virus	O
in	O
the	O
general	O
population	O
of	O
Hisayama	O
,	O
Japan	O
:	O
significance	O
of	O
isolated	O
antibody	O
to	O
hepatitis	B-GENE
B	I-GENE
surface	I-GENE
antigen	I-GENE
in	O
general	O
population	O
.	O


On	O
the	O
other	O
hand	O
,	O
neither	O
phosphate	O
buffered	O
saline	O
injection	O
into	O
the	O
ES	O
nor	O
primary	O
KLH	B-GENE
challenges	O
of	O
the	O
ES	O
were	O
capable	O
of	O
elevating	O
the	O
threshold	O
level	O
and	O
changing	O
the	O
latency	O
.	O


Previously	O
,	O
we	O
showed	O
that	O
SNF2	B-GENE
,	O
SNF5	B-GENE
,	O
and	O
SNF6	B-GENE
function	O
interdependently	O
in	O
transcriptional	O
activation	O
,	O
possibly	O
forming	O
a	O
heteromeric	O
complex	O
.	O


NE	B-GENE
and	O
PR3	B-GENE
assist	O
in	O
the	O
destruction	O
of	O
phagocytosed	O
microorganisms	O
,	O
cleave	O
the	O
important	O
connective	B-GENE
-	I-GENE
tissue	I-GENE
protein	I-GENE
elastin	I-GENE
,	O
and	O
generate	O
chemotactic	O
activities	O
by	O
forming	O
alpha	B-GENE
1	I-GENE
-	I-GENE
proteinase	I-GENE
inhibitor	I-GENE
complexes	I-GENE
and	O
elastin	B-GENE
peptides	I-GENE
.	O


By	O
contrast	O
,	O
d	B-GENE
(	I-GENE
T2AG3T	I-GENE
)	I-GENE
and	O
d	B-GENE
(	I-GENE
T2G4T	I-GENE
)	I-GENE
form	O
only	O
the	O
G	O
-	O
quadruplex	O
monomer	O
structures	O
independent	O
of	O
K	O
cation	O
concentration	O
as	O
reported	O
previously	O
[	O
Sen	O
,	O
D	O
.	O
,	O
&	O
Gilbert	O
,	O
W	O
.	O


Exon	O
-	O
intron	O
junctions	O
in	O
the	O
human	O
and	O
rat	B-GENE
AdoMet	I-GENE
decarboxylase	I-GENE
genes	I-GENE
were	O
in	O
identical	O
positions	O
except	O
that	O
exons	O
6	O
and	O
7	O
of	O
the	O
human	O
gene	O
formed	O
a	O
single	O
exon	O
in	O
the	O
rat	O
gene	O
.	O


Among	O
the	O
few	O
proteins	O
of	O
the	O
eukaryotic	O
nucleolus	O
that	O
have	O
been	O
characterized	O
,	O
four	O
proteins	O
,	O
nucleolin	B-GENE
,	O
fibrillarin	B-GENE
,	O
SSB1	B-GENE
and	O
NSR1	B-GENE
,	O
possess	O
a	O
common	O
structural	O
motif	O
,	O
the	O
GAR	O
domain	O
,	O
which	O
is	O
rich	O
in	O
glycine	O
and	O
arginine	O
residues	O
.	O


Mutations	O
in	O
either	O
gene	O
block	O
some	O
crucial	O
late	O
step	O
in	O
assembly	O
of	O
F1	B-GENE
,	O
causing	O
the	O
alpha	O
and	O
beta	O
subunits	O
to	O
accumulate	O
in	O
mitochondria	O
as	O
inactive	O
aggregates	O
(	O
Ackerman	O
,	O
S	O
.	O


There	O
was	O
however	O
,	O
no	O
significant	O
difference	O
in	O
the	O
prevalence	O
of	O
chronic	O
respiratory	O
symptoms	O
between	O
animal	O
food	O
workers	O
with	O
positive	O
and	O
negative	O
skin	O
tests	O
to	O
house	O
dust	O
or	O
to	O
fish	O
flour	O
or	O
among	O
those	O
with	O
increased	O
or	O
normal	O
IgE	B-GENE
(	O
except	O
for	O
dyspnea	O
)	O
.	O


A	O
13	O
base	O
-	O
pair	O
oligonucleotide	O
spanning	O
nucleotides	O
+	O
80	O
to	O
+	O
92	O
of	O
the	O
5	B-GENE
S	I-GENE
RNA	I-GENE
gene	I-GENE
retained	O
specific	O
and	O
high	O
-	O
affinity	O
binding	O
,	O
although	O
the	O
latter	O
was	O
reduced	O
sixfold	O
relative	O
to	O
longer	O
DNA	O
fragments	O
.	O


Moreover	O
,	O
the	O
reconstitution	O
of	O
eUSF	B-GENE
and	O
TFIID	B-GENE
-	O
depleted	O
transcription	O
complexes	O
with	O
purified	O
protein	O
fractions	O
demonstrate	O
that	O
not	O
only	O
TFIID	B-GENE
but	O
also	O
eUSF	B-GENE
essentially	O
participates	O
in	O
complex	O
formation	O
even	O
on	O
H5	B-GENE
promoter	I-GENE
mutations	O
lacking	O
the	O
TATA	O
-	O
box	O
.	O


The	O
gene	O
encoding	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
was	O
previously	O
found	O
to	O
contain	O
an	O
intronic	O
enhancer	O
element	O
that	O
was	O
not	O
tissue	O
-	O
specific	O
in	O
its	O
activity	O
,	O
despite	O
the	O
restricted	O
expression	O
of	O
the	O
intact	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
-	I-GENE
encoding	I-GENE
gene	I-GENE
.	O


Molecular	O
cloning	O
of	O
the	O
polypeptide	O
component	O
of	O
the	O
Rel	B-GENE
-	I-GENE
related	I-GENE
human	I-GENE
p75	I-GENE
nucleoprotein	I-GENE
complex	I-GENE
has	O
revealed	O
its	O
identity	O
with	O
the	O
65	O
-	O
kDa	O
(	O
p65	B-GENE
)	O
subunit	O
of	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
.	O


Within	O
the	O
human	O
enhancer	O
,	O
these	O
two	O
sites	O
are	O
located	O
within	O
the	O
previously	O
defined	O
DNase	B-GENE
I	I-GENE
footprints	I-GENE
,	O
NFAT	B-GENE
-	I-GENE
1	I-GENE
and	O
NFIL	B-GENE
-	I-GENE
2B	I-GENE
,	O
respectively	O
.	O


The	O
cardiac	B-GENE
myosin	I-GENE
light	I-GENE
chain	I-GENE
-	I-GENE
2	I-GENE
(	O
MLC	B-GENE
-	I-GENE
2	I-GENE
)	O
gene	O
promoter	O
contains	O
several	O
positive	O
and	O
negative	O
cis	O
-	O
acting	O
sequences	O
that	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
its	O
expression	O
.	O


Disruption	O
mutations	O
have	O
been	O
constructed	O
in	O
the	O
SLK1	B-GENE
gene	I-GENE
.	O
slk1	B-GENE
null	I-GENE
mutants	I-GENE
cannot	O
grow	O
at	O
37	O
degrees	O
C	O
,	O
but	O
many	O
cells	O
can	O
grow	O
at	O
30	O
,	O
24	O
,	O
and	O
17	O
degrees	O
C	O
.	O


A	O
32P	O
-	O
labeled	O
LAP	B-GENE
DNA	O
-	O
binding	O
and	O
dimerization	O
domain	O
"	O
zipper	O
probe	O
"	O
was	O
used	O
to	O
isolate	O
a	O
clone	O
that	O
encodes	O
a	O
new	O
C	B-GENE
/	I-GENE
EBP	I-GENE
-	I-GENE
homologous	I-GENE
protein	I-GENE
:	O
CHOP	B-GENE
-	I-GENE
10	I-GENE
.	O


Stringent	O
hybridization	O
of	O
EHS	B-GENE
-	I-GENE
1	I-GENE
back	O
to	O
primate	O
genomic	O
DNA	O
indicates	O
two	O
distinct	O
EHS	B-GENE
-	I-GENE
1	I-GENE
loci	I-GENE
in	O
normal	O
human	O
DNA	O
,	O
an	O
identical	O
band	O
pattern	O
in	O
chimpanzee	O
DNA	O
,	O
and	O
a	O
single	O
locus	O
in	O
rhesus	O
monkey	O
DNA	O
.	O


The	O
functions	O
of	O
isolated	O
portions	O
of	O
the	O
insulin	B-GENE
,	O
IAPP	B-GENE
,	O
and	O
beta	B-GENE
GK	I-GENE
promoters	I-GENE
were	O
studied	O
by	O
using	O
transient	O
expression	O
and	O
DNA	O
binding	O
assays	O
.	O


The	O
c	B-GENE
-	I-GENE
Ets	I-GENE
-	I-GENE
1	I-GENE
oncoprotein	I-GENE
is	O
a	O
transcription	O
activator	O
that	O
specifically	O
binds	O
to	O
DNA	O
.	O


Hence	O
temperature	O
and	O
virF	B-GENE
are	O
both	O
required	O
for	O
the	O
induction	O
of	O
the	O
yop	B-GENE
regulon	I-GENE
.	O


To	O
determine	O
the	O
genetic	O
basis	O
for	O
the	O
differences	O
between	O
the	O
cardiac	O
and	O
brain	B-GENE
AE3	I-GENE
variants	I-GENE
,	O
we	O
isolated	O
and	O
characterized	O
the	O
rat	O
gene	O
.	O


Overproduction	O
,	O
purification	O
and	O
characterization	O
of	O
M	B-GENE
.	I-GENE
HinfI	I-GENE
methyltransferase	I-GENE
and	O
its	O
deletion	O
mutant	O
.	O


Hybridization	O
data	O
indicate	O
that	O
6F6	B-GENE
.	I-GENE
2	I-GENE
corresponds	O
to	O
the	O
previously	O
characterized	O
m6F6	B-GENE
cDNA	I-GENE
clone	I-GENE
and	O
that	O
6F6	B-GENE
.	I-GENE
1	I-GENE
and	O
6F6	B-GENE
.	I-GENE
3	I-GENE
,	O
but	O
not	O
6F6	B-GENE
.	I-GENE
2	I-GENE
,	O
are	O
adjacent	O
to	O
alpha	B-GENE
-	I-GENE
type	I-GENE
genes	I-GENE
.	O


The	O
IA4	B-GENE
mAb	I-GENE
was	O
identified	O
among	O
a	O
series	O
of	O
antibodies	O
raised	O
in	O
BALB	O
/	O
c	O
mice	O
after	O
immunization	O
against	O
a	O
HLA	B-GENE
class	O
I	O
-	O
deficient	O
,	O
lymphokine	O
-	O
activated	O
killer	O
(	O
LAK	O
)	O
-	O
susceptible	O
EBV	O
-	O
B	O
lymphocyte	O
line	O
.	O


Two	O
variant	O
PRP	B-GENE
-	I-GENE
precursor	I-GENE
alleles	I-GENE
occur	O
which	O
slightly	O
differ	O
in	O
the	O
number	O
of	O
repeats	O
in	O
domain	O
C	O
.	O


Dimerization	O
of	O
Myf	B-GENE
-	I-GENE
5	I-GENE
with	O
the	O
ubiquitously	O
expressed	O
bHLH	O
protein	O
E12	B-GENE
not	O
only	O
increases	O
the	O
affinity	O
for	O
DNA	O
but	O
also	O
stimulates	O
transactivation	O
independently	O
of	O
DNA	O
binding	O
.	O


Neural	O
-	O
specific	O
expression	O
,	O
genomic	O
structure	O
,	O
and	O
chromosomal	O
localization	O
of	O
the	O
gene	O
encoding	O
the	O
zinc	B-GENE
-	I-GENE
finger	I-GENE
transcription	I-GENE
factor	I-GENE
NGFI	I-GENE
-	I-GENE
C	I-GENE
.	O


STP1	B-GENE
is	O
an	O
unessential	O
yeast	O
gene	O
involved	O
in	O
the	O
removal	O
of	O
intervening	O
sequences	O
from	O
some	O
,	O
but	O
not	O
all	O
,	O
families	O
of	O
intervening	O
sequence	O
-	O
containing	O
pre	O
-	O
tRNAs	O
.	O


Using	O
these	O
antibodies	O
,	O
we	O
were	O
able	O
to	O
define	O
the	O
conditions	O
to	O
completely	O
solubilize	O
the	O
Cdc25	B-GENE
protein	I-GENE
.	O


Disruption	O
demonstrates	O
that	O
CDC14	B-GENE
is	O
an	O
essential	O
gene	O
.	O


His	O
HC	B-GENE
II	I-GENE
activity	O
and	O
antigen	O
levels	O
were	O
49	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
and	O
his	O
daughter	O
also	O
showed	O
similar	O
low	O
levels	O
.	O


Furthermore	O
,	O
no	O
transcripts	O
of	O
the	O
same	O
size	O
and	O
having	O
the	O
same	O
developmental	O
profile	O
as	O
those	O
generated	O
by	O
the	O
wild	B-GENE
-	I-GENE
type	I-GENE
E10	I-GENE
fragment	I-GENE
were	O
identified	O
by	O
probes	O
covering	O
the	O
remainder	O
of	O
the	O
cloned	O
region	O
.	O


The	O
sequence	O
-	O
specific	O
interaction	O
of	O
nuclear	B-GENE
factor	I-GENE
HiNF	I-GENE
-	I-GENE
D	I-GENE
with	O
this	O
key	O
proximal	O
promoter	O
element	O
of	O
the	O
H4	B-GENE
-	I-GENE
FO108	I-GENE
gene	I-GENE
is	O
cell	O
cycle	O
regulated	O
in	O
normal	O
diploid	O
cells	O
(	O
J	O
.	O


Two	O
cDNAs	O
encoding	O
casein	B-GENE
kinase	I-GENE
-	I-GENE
1	I-GENE
have	O
been	O
isolated	O
from	O
a	O
yeast	O
cDNA	O
library	O
and	O
termed	O
CKI1	B-GENE
and	O
CKI2	B-GENE
.	O


A	O
38	O
-	O
bp	O
poly	O
(	O
dA	O
-	O
dT	O
)	O
region	O
was	O
found	O
to	O
be	O
a	O
positive	O
regulator	O
of	O
Act1	B-GENE
promoter	I-GENE
activity	O
.	O


The	O
DRF	B-GENE
-	I-GENE
2	I-GENE
nuclear	I-GENE
protein	I-GENE
has	O
characteristics	O
similar	O
to	O
those	O
of	O
the	O
muscle	O
-	O
specific	O
regulatory	O
factor	O
,	O
MEF	B-GENE
-	I-GENE
2	I-GENE
(	O
Buskin	O
and	O
Hauschka	O
1989	O
;	O
Gossett	O
et	O
al	O
.	O
,	O
1989	O
)	O
.	O


From	O
the	O
15	O
-	O
kb	O
clone	O
a	O
4	B-GENE
-	I-GENE
kb	I-GENE
EcoRI	I-GENE
fragment	I-GENE
containing	O
the	O
first	O
two	O
exons	O
and	O
2	O
.	O
6	O
kb	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
opn	B-GENE
gene	I-GENE
was	O
sequenced	O
,	O
and	O
the	O
transcriptional	O
start	O
site	O
determined	O
by	O
primer	O
extension	O
analysis	O
and	O
S1	B-GENE
nuclease	I-GENE
mapping	O
.	O


This	O
open	O
reading	O
frame	O
was	O
confirmed	O
the	O
correct	O
one	O
by	O
direct	O
amino	O
-	O
terminal	O
sequence	O
analysis	O
of	O
the	O
overproduced	O
msgB	B-GENE
gene	I-GENE
product	I-GENE
.	O


The	O
virus	O
encodes	O
a	O
40	O
-	O
kDa	O
protein	O
,	O
tax	B-GENE
,	O
that	O
is	O
important	O
for	O
the	O
immortalization	O
of	O
T	O
cells	O
.	O


An	O
examination	O
of	O
the	O
role	O
of	O
the	O
carboxyl	O
terminus	O
in	O
regulating	O
NGFI	B-GENE
-	I-GENE
B	I-GENE
transcriptional	O
activity	O
revealed	O
that	O
,	O
in	O
accordance	O
with	O
other	O
nuclear	O
receptors	O
,	O
mutants	O
lacking	O
portions	O
of	O
the	O
carboxyl	O
terminus	O
had	O
greatly	O
decreased	O
activity	O
.	O


Altogether	O
these	O
results	O
indicate	O
that	O
the	O
Syn	B-GENE
5	I-GENE
locus	I-GENE
segregates	O
from	O
the	O
gene	O
specifying	O
gH	B-GENE
,	O
to	O
a	O
region	O
encompassing	O
portions	O
of	O
the	O
TK	B-GENE
and	O
UL	B-GENE
24	I-GENE
genes	I-GENE
,	O
and	O
that	O
the	O
syn	B-GENE
mutation	I-GENE
does	O
not	O
affect	O
the	O
expression	O
or	O
activity	O
of	O
TK	B-GENE
.	O


We	O
identify	O
the	O
"	O
M	O
region	O
"	O
of	O
the	O
muscle	B-GENE
-	I-GENE
specific	I-GENE
Xenopus	I-GENE
cardiac	I-GENE
actin	I-GENE
gene	I-GENE
promoter	I-GENE
from	O
-	O
282	O
to	O
-	O
348	O
as	O
necessary	O
for	O
the	O
embryonic	O
expression	O
of	O
a	O
cardiac	O
actin	B-GENE
-	O
beta	B-GENE
-	I-GENE
globin	I-GENE
reporter	O
gene	O
injected	O
into	O
fertilized	O
eggs	O
.	O


In	O
addition	O
to	O
the	O
previously	O
identified	O
and	O
characterized	O
attenuator	B-GENE
1	I-GENE
situated	O
93	O
nucleotides	O
downstream	O
from	O
the	O
major	O
late	O
transcription	O
start	O
site	O
,	O
a	O
second	O
attenuator	O
,	O
attenuator	B-GENE
2	I-GENE
,	O
situated	O
55	O
nucleotides	O
downstream	O
from	O
it	O
,	O
has	O
been	O
identified	O
.	O


These	O
experiments	O
delineate	O
a	O
186	O
-	O
bp	O
,	O
EBNA	B-GENE
-	I-GENE
2	I-GENE
-	O
responsive	O
cell	O
DNA	O
fragment	O
and	O
provide	O
firm	O
evidence	O
that	O
EBNA	B-GENE
-	I-GENE
2	I-GENE
transactivates	O
transcription	O
of	O
cell	O
genes	O
.	O


We	O
have	O
isolated	O
and	O
sequenced	O
two	O
overlapping	O
cDNA	O
fragments	O
which	O
could	O
encode	O
the	O
complete	O
amino	O
acid	O
sequence	O
of	O
rat	B-GENE
testis	I-GENE
fructose	I-GENE
-	I-GENE
6	I-GENE
-	I-GENE
phosphate	I-GENE
,	I-GENE
2	I-GENE
-	I-GENE
kinase	I-GENE
:	O
fructose	B-GENE
-	I-GENE
2	I-GENE
,	I-GENE
6	I-GENE
-	I-GENE
bisphosphatase	I-GENE
.	O


In	O
similar	O
transient	O
transfection	O
experiments	O
in	O
HeLa	O
cells	O
,	O
overexpression	O
of	O
the	O
wt	B-GENE
human	I-GENE
retinoblastoma	I-GENE
susceptibility	I-GENE
gene	I-GENE
product	I-GENE
,	O
RB	B-GENE
,	O
was	O
found	O
to	O
repress	O
the	O
serum	O
-	O
induced	O
IL	B-GENE
-	I-GENE
6	I-GENE
(	O
-	O
225	O
to	O
+	O
13	O
)	O
,	O
c	B-GENE
-	I-GENE
fos	I-GENE
(	O
-	O
711	O
to	O
+	O
42	O
)	O
,	O
and	O
beta	B-GENE
-	I-GENE
actin	I-GENE
(	O
-	O
3400	O
to	O
+	O
912	O
)	O
promoters	O
but	O
not	O
the	O
PRV	O
-	O
induced	O
IL	B-GENE
-	I-GENE
6	I-GENE
(	O
-	O
110	O
to	O
+	O
13	O
)	O
or	O
the	O
serum	O
-	O
induced	O
MHC	B-GENE
(	O
-	O
528	O
to	O
-	O
38	O
)	O
promoters	O
.	O


This	O
repression	O
was	O
mediated	O
through	O
binding	O
to	O
the	O
E2	B-GENE
DNA	I-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
immediately	O
upstream	O
of	O
the	O
P105	B-GENE
promoter	O
TATA	O
box	O
and	O
could	O
be	O
abrogated	O
by	O
preincubation	O
of	O
the	O
HPV	B-GENE
-	I-GENE
18	I-GENE
P105	I-GENE
promoter	I-GENE
template	O
with	O
the	O
nuclear	O
extract	O
allowing	O
the	O
formation	O
of	O
the	O
preinitiation	O
complex	O
.	O


TPA	O
and	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
1	I-GENE
did	O
not	O
markedly	O
affect	O
the	O
activities	O
of	O
the	O
72	O
-	O
kDa	O
enzyme	O
.	O


Alignment	O
of	O
the	O
amino	O
acid	O
sequences	O
surrounding	O
Tyr	O
-	O
766	O
with	O
corresponding	O
regions	O
of	O
other	O
FGFRs	B-GENE
revealed	O
conserved	O
tyrosine	O
residues	O
in	O
all	O
known	O
members	O
of	O
the	O
FGFR	B-GENE
family	I-GENE
.	O


Intron	O
K1	B-GENE
cox1	I-GENE
.	I-GENE
2	I-GENE
is	O
not	O
found	O
in	O
S	O
.	O
cerevisiae	O
and	O
appears	O
at	O
an	O
unique	O
location	O
in	O
K	O
.	O
lactis	O
.	O


Recombination	O
between	O
feline	O
leukemia	O
virus	O
subgroup	O
B	O
or	O
C	O
and	O
endogenous	O
env	B-GENE
elements	O
alters	O
the	O
in	O
vitro	O
biological	O
activities	O
of	O
the	O
viruses	O
.	O


The	O
strategy	O
has	O
been	O
used	O
to	O
determine	O
2	O
.	O
6	O
kilobases	O
of	O
nucleotide	O
sequence	O
in	O
the	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
ADE	I-GENE
1	I-GENE
locus	I-GENE
.	O


Two	O
independent	O
promoters	O
as	O
well	O
as	O
5	O
'	O
untranslated	O
regions	O
regulate	O
Dd	B-GENE
ras	I-GENE
expression	O
in	O
Dictyostelium	O
.	O


The	O
two	O
genes	O
code	O
for	O
polypeptides	B-GENE
of	I-GENE
420	I-GENE
amino	I-GENE
acids	I-GENE
(	I-GENE
M	I-GENE
.	I-GENE
HgiCI	I-GENE
)	I-GENE
and	O
345	B-GENE
amino	I-GENE
acids	I-GENE
(	I-GENE
R	I-GENE
.	I-GENE
HgiCI	I-GENE
)	I-GENE
.	O


The	O
factor	O
which	O
binds	O
to	O
the	O
TR	B-GENE
promoter	I-GENE
co	O
-	O
sedimented	O
with	O
SV40	O
chromosomes	O
extracted	O
late	O
in	O
infection	O
.	O


The	O
resulting	O
clone	O
pKB11	B-GENE
,	O
which	O
has	O
a	O
1369	O
-	O
base	O
pair	O
(	O
bp	O
)	O
cDNA	O
insert	O
,	O
overlapping	O
pCAD142	B-GENE
by	O
781	O
bp	O
,	O
was	O
identified	O
by	O
hybridization	O
methods	O
and	O
sequence	O
analysis	O
and	O
found	O
to	O
contain	O
the	O
entire	O
cDNA	O
sequence	O
for	O
the	O
amino	O
end	O
of	O
the	O
CAD	B-GENE
polypeptide	I-GENE
.	O


Its	O
clearance	O
has	O
been	O
found	O
to	O
be	O
decreased	O
(	O
typically	O
by	O
around	O
25	O
%	O
,	O
but	O
often	O
by	O
far	O
more	O
)	O
by	O
erythromycin	O
,	O
troleandomycin	O
(	O
triacetyloleandomycin	O
)	O
,	O
roxithromycin	O
,	O
enoxacin	O
,	O
ciprofloxacin	O
,	O
pefloxacin	O
,	O
norfloxacin	O
,	O
ofloxacin	O
,	O
fluoroquinolone	O
T	O
-	O
3262	O
,	O
pipemidic	O
acid	O
,	O
cimetidine	O
,	O
etintidine	O
,	O
propranolol	O
,	O
verapamil	O
,	O
diltiazem	O
,	O
nifedipine	O
,	O
furosemide	O
(	O
frusemide	O
)	O
,	O
at	O
least	O
some	O
anovulent	O
agents	O
,	O
viloxazine	O
,	O
allopurinol	O
,	O
ticlopidine	O
,	O
idrocilamide	O
,	O
thiabendazole	O
,	O
disulfiram	O
,	O
influenza	O
-	O
and	O
BCG	O
-	O
vaccination	O
,	O
interferon	B-GENE
,	O
and	O
caffeine	O
(	O
half	O
-	O
life	O
increase	O
)	O
.	O


No	O
homology	O
was	O
found	O
between	O
RNA14	B-GENE
and	O
RNA15	B-GENE
or	O
between	O
RNA14	B-GENE
and	O
other	O
proteins	O
contained	O
in	O
data	O
banks	O
.	O


The	O
most	O
striking	O
difference	O
in	O
the	O
birch	B-GENE
NAD	I-GENE
(	I-GENE
P	I-GENE
)	I-GENE
H	I-GENE
-	I-GENE
NR	I-GENE
sequence	I-GENE
in	O
comparison	O
to	O
NADH	B-GENE
-	I-GENE
NR	I-GENE
sequences	I-GENE
was	O
found	O
at	O
the	O
putative	O
pyridine	O
nucleotide	O
binding	O
site	O
.	O


The	O
localization	O
of	O
this	O
proteoglycan	O
locus	O
in	O
the	O
human	O
genome	O
and	O
the	O
availability	O
of	O
new	O
RFLPs	O
provide	O
the	O
tools	O
for	O
future	O
studies	O
of	O
human	O
diseases	O
where	O
the	O
HSPG2	B-GENE
proteoglycan	I-GENE
gene	I-GENE
is	O
suspected	O
to	O
be	O
involved	O
.	O


The	O
cis	O
-	O
acting	O
element	O
mediating	O
glucocorticoid	O
inducibility	O
of	O
the	O
chicken	B-GENE
glutamine	I-GENE
synthetase	I-GENE
gene	I-GENE
has	O
been	O
identified	O
.	O


Expression	O
of	O
six	O
genes	O
,	O
ipaB	B-GENE
,	O
ipaC	B-GENE
,	O
invE	B-GENE
,	O
invG	B-GENE
,	O
invJ	B-GENE
,	O
and	O
invK	B-GENE
,	O
was	O
apparently	O
regulated	O
by	O
the	O
positive	O
regulator	O
virF	B-GENE
.	O


The	O
presence	O
of	O
the	O
corresponding	O
mature	O
mRNA	O
transcripts	O
(	O
3	O
.	O
2	O
-	O
3	O
.	O
5	O
kilobase	O
pairs	O
(	O
kb	O
]	O
in	O
human	O
fibroblasts	O
was	O
shown	O
by	O
Northern	O
blot	O
hybridization	O
,	O
S1	B-GENE
nuclease	I-GENE
protection	O
assay	O
,	O
and	O
the	O
polymerase	O
chain	O
reaction	O
.	O


However	O
,	O
the	O
rtFc	B-GENE
gamma	I-GENE
R	I-GENE
alpha	I-GENE
cDNA	I-GENE
clone	O
is	O
complementary	O
to	O
at	O
least	O
two	O
different	O
-	O
sized	O
mRNAs	O
expressed	O
by	O
CRNK	O
-	O
16	O
cells	O
,	O
contrasting	O
the	O
single	O
Fc	B-GENE
gamma	I-GENE
R	I-GENE
-	I-GENE
related	I-GENE
mRNA	I-GENE
species	O
expressed	O
by	O
human	O
and	O
mouse	O
natural	O
killer	O
cells	O
.	O


Treatment	O
of	O
human	O
myeloid	O
cell	O
lines	O
HL	O
-	O
60	O
and	O
U937	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
increased	O
within	O
2	O
h	O
cellular	O
levels	O
of	O
the	O
RNA	O
hybridizable	O
to	O
LD78	B-GENE
cDNA	I-GENE
.	O


Serum	O
IgG	B-GENE
was	O
initially	O
elevated	O
in	O
6	O
patients	O
.	O


Induction	O
of	O
Jurkat	O
leukemic	O
T	O
cells	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
ionomycin	O
did	O
not	O
affect	O
the	O
level	O
of	O
FKBP	B-GENE
mRNA	I-GENE
.	O


Identification	O
and	O
characterization	O
of	O
the	O
promoter	O
for	O
the	O
cytotactin	B-GENE
gene	I-GENE
.	O


Co	O
-	O
existence	O
of	O
these	O
regulatory	O
elements	O
with	O
other	O
elements	O
,	O
such	O
as	O
the	O
AP	B-GENE
-	I-GENE
2	I-GENE
element	I-GENE
or	O
CCAAT	O
box	O
,	O
was	O
also	O
found	O
.	O


Since	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
this	O
gene	O
is	O
likely	O
involved	O
in	O
hormonal	O
regulation	O
of	O
its	O
expression	O
,	O
we	O
have	O
isolated	O
and	O
partially	O
characterized	O
an	O
avian	O
fatty	B-GENE
acid	I-GENE
synthase	I-GENE
gene	O
.	O


Whereas	O
cDNA	O
hybridization	O
to	O
genomic	O
DNA	O
blots	O
indicated	O
a	O
small	O
subfamily	O
of	O
G0S19	B-GENE
genes	I-GENE
,	O
simple	O
patterns	O
of	O
bands	O
indicated	O
that	O
most	O
cDNAs	O
,	O
including	O
G0S30	B-GENE
cDNA	I-GENE
,	O
corresponded	O
to	O
single	O
-	O
copy	O
genes	O
.	O


The	O
DNA	O
sequence	O
conferring	O
AP	B-GENE
-	I-GENE
1	I-GENE
activity	O
was	O
located	O
in	O
the	O
proximal	O
promoter	O
region	O
.	O


The	O
murine	B-GENE
mutation	I-GENE
dominant	I-GENE
white	I-GENE
spotting	I-GENE
(	O
W	B-GENE
)	O
is	O
in	O
the	O
proto	O
-	O
oncogene	O
,	O
c	B-GENE
-	I-GENE
kit	I-GENE
.	O


These	O
clones	O
overlapped	O
and	O
contained	O
the	O
structural	O
gene	O
encoding	O
the	O
complete	O
C5	B-GENE
alpha	I-GENE
-	I-GENE
chain	I-GENE
and	O
90	O
%	O
of	O
the	O
beta	O
-	O
chain	O
.	O


Heterozygous	O
mutation	O
in	O
the	O
G	O
+	O
5	O
position	O
of	O
intron	O
33	O
of	O
the	O
pro	B-GENE
-	I-GENE
alpha	I-GENE
2	I-GENE
(	I-GENE
I	I-GENE
)	I-GENE
gene	I-GENE
(	O
COL1A2	B-GENE
)	O
that	O
causes	O
aberrant	O
RNA	O
splicing	O
and	O
lethal	O
osteogenesis	O
imperfecta	O
.	O


A	O
full	B-GENE
-	I-GENE
length	I-GENE
human	I-GENE
pim	I-GENE
-	I-GENE
1	I-GENE
cDNA	I-GENE
was	O
subcloned	O
into	O
the	O
bacterial	O
vector	O
pGEX	O
-	O
2T	O
and	O
the	O
Pim	B-GENE
-	I-GENE
1	I-GENE
protein	I-GENE
expressed	O
as	O
a	O
fusion	O
product	O
with	O
bacterial	B-GENE
glutathione	I-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
(	O
GST	B-GENE
)	O
.	O


Opposite	O
effects	O
of	O
CYP1	B-GENE
are	O
observed	O
in	O
aerobic	O
,	O
heme	O
-	O
sufficient	O
cells	O
.	O


A	O
segmental	O
analysis	O
of	O
the	O
key	O
regions	O
of	O
HLA	B-GENE
-	I-GENE
DR1	I-GENE
that	O
control	O
T	O
cell	O
allorecognition	O
was	O
performed	O
by	O
using	O
a	O
series	O
of	O
transfected	O
cell	O
lines	O
expressing	O
the	O
products	O
of	O
recombinant	O
DRB	B-GENE
/	O
H	B-GENE
-	I-GENE
2Eb	I-GENE
genes	O
,	O
paired	O
with	O
either	O
DR	B-GENE
alpha	I-GENE
or	O
H	B-GENE
-	I-GENE
2E	I-GENE
alpha	I-GENE
.	O


The	O
alpha	B-GENE
inhibin	I-GENE
promoter	I-GENE
containing	O
a	O
mutated	O
CRE	O
was	O
not	O
regulated	O
by	O
forskolin	O
in	O
granulosa	O
cells	O
and	O
did	O
not	O
bind	O
the	O
CREB	B-GENE
protein	I-GENE
.	O


These	O
results	O
indicate	O
that	O
the	O
sulfhydryl	O
group	O
of	O
certain	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
inhibitors	O
can	O
potentiate	O
their	O
effect	O
on	O
the	O
endogenous	O
nitrovasodilator	O
EDRF	B-GENE
.	O


A	O
second	O
even	O
more	O
significant	O
match	O
to	O
this	O
E	O
.	O
coli	O
region	O
was	O
found	O
in	O
the	O
retroviral	B-GENE
ribonuclease	I-GENE
H	I-GENE
(	O
RNase	B-GENE
H	I-GENE
)	O
domain	O
,	O
and	O
corresponds	O
precisely	O
to	O
a	O
region	O
that	O
has	O
been	O
aligned	O
by	O
previous	O
investigators	O
with	O
the	O
E	B-GENE
.	I-GENE
coli	I-GENE
RNase	I-GENE
H	I-GENE
,	O
suggesting	O
that	O
Pol	B-GENE
I	I-GENE
helices	O
O	O
and	O
P	O
are	O
homologous	O
to	O
helices	O
A	O
and	O
D	O
of	O
the	O
RNase	B-GENE
H	I-GENE
crystal	O
structure	O
,	O
respectively	O
.	O


The	O
qualitative	O
concentrations	O
of	O
HCG	B-GENE
had	O
a	O
sensitivity	O
of	O
37	O
.	O
5	O
%	O
and	O
a	O
specificity	O
of	O
100	O
%	O
.	O


They	O
were	O
checked	O
for	O
anti	B-GENE
-	I-GENE
HCV	I-GENE
(	O
anti	B-GENE
-	I-GENE
C100	I-GENE
-	I-GENE
3	I-GENE
)	O
with	O
HCV	O
EIA	O
kit	O
(	O
Abbott	O
Lab	O
.	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O


Max	B-GENE
:	O
functional	O
domains	O
and	O
interaction	O
with	O
c	B-GENE
-	I-GENE
Myc	I-GENE
.	O


Zn	O
(	O
II	O
)	O
coordination	O
domain	O
mutants	O
of	O
T4	O
gene	B-GENE
32	I-GENE
protein	O
.	O


The	O
tissue	O
specificity	O
of	O
gene	O
expression	O
was	O
identical	O
to	O
that	O
described	O
previously	O
for	O
the	O
CaMV	B-GENE
35S	I-GENE
domain	I-GENE
B	I-GENE
enhancer	I-GENE
element	I-GENE
.	O


Immunostaining	O
of	O
cells	O
transfected	O
with	O
these	O
constructs	O
revealed	O
that	O
both	O
the	O
myristoylated	O
and	O
nonmyristoylated	O
mutants	O
were	O
localized	O
in	O
nuclei	O
,	O
whereas	O
wild	B-GENE
-	I-GENE
type	I-GENE
PKC	I-GENE
alpha	I-GENE
was	O
primarily	O
cytoplasmic	O
and	O
perinuclear	O
.	O


We	O
have	O
partially	O
sequenced	O
the	O
RAP74	B-GENE
protein	I-GENE
from	O
purified	O
HeLa	O
cells	O
,	O
cloned	O
its	O
complementary	O
DNA	O
and	O
shown	O
that	O
its	O
translation	O
product	O
can	O
interact	O
with	O
RAP30	B-GENE
in	O
vitro	O
as	O
well	O
as	O
in	O
vivo	O
.	O


The	O
size	O
of	O
the	O
mutant	O
molecule	O
corresponds	O
to	O
the	O
unprocessed	O
cytoplasmic	O
precursor	O
(	O
pre	B-GENE
-	I-GENE
super	I-GENE
-	I-GENE
pro	I-GENE
-	I-GENE
PrB	I-GENE
)	O
,	O
as	O
detected	O
in	O
sec61	B-GENE
mutants	I-GENE
,	O
when	O
translocation	O
into	O
the	O
endoplasmic	O
reticulum	O
is	O
blocked	O
.	O


The	O
predicted	O
amino	O
acid	O
sequence	O
exhibited	O
70	O
%	O
identity	O
to	O
that	O
of	O
Bacillus	B-GENE
stearothermophilus	I-GENE
TyrTS	I-GENE
and	O
55	O
%	O
identity	O
to	O
that	O
of	O
E	B-GENE
.	I-GENE
coli	I-GENE
TyrTS	I-GENE
,	O
while	O
identity	O
to	O
a	O
second	O
cryptic	O
B	B-GENE
.	I-GENE
subtilis	I-GENE
TyrTS	I-GENE
gene	I-GENE
,	O
designated	O
tyrZ	B-GENE
,	O
was	O
only	O
27	O
%	O
.	O


BACKGROUND	O
:	O
The	O
effectiveness	O
of	O
monoamine	B-GENE
oxidase	I-GENE
inhibitors	O
(	O
MAOIs	O
)	O
in	O
tricyclic	O
resistant	O
depression	O
has	O
received	O
surprisingly	O
little	O
systematic	O
study	O
.	O


To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
overexpressed	O
Kex2p	B-GENE
using	O
the	O
baculovirus	O
/	O
insect	O
cell	O
expression	O
system	O
.	O


RESULTS	O
:	O
Plasma	B-GENE
AVP	I-GENE
responses	O
to	O
osmotic	O
stimulation	O
,	O
and	O
non	O
-	O
osmotic	O
inhibition	O
by	O
drinking	O
,	O
were	O
normal	O
in	O
patients	O
with	O
compulsive	O
water	O
drinking	O
.	O


Human	O
SRF	B-GENE
-	I-GENE
related	I-GENE
proteins	I-GENE
:	O
DNA	O
-	O
binding	O
properties	O
and	O
potential	O
regulatory	O
targets	O
.	O


Growth	O
factor	O
stimulation	O
of	O
cells	O
causes	O
the	O
phosphorylation	O
of	O
the	O
c	B-GENE
-	I-GENE
Myc	I-GENE
transcriptional	I-GENE
activation	I-GENE
domain	I-GENE
at	O
Ser62	O
within	O
a	O
proline	O
-	O
rich	O
region	O
that	O
is	O
highly	O
conserved	O
among	O
members	O
of	O
the	O
Myc	B-GENE
family	I-GENE
(	O
Alvarez	O
,	O
E	O
.	O
,	O
Northwood	O
,	O
I	O
.	O
C	O
.	O
,	O
Gonzalez	O
,	O
F	O
.	O


As	O
an	O
initial	O
step	O
towards	O
the	O
characterization	O
of	O
replicative	O
DNA	B-GENE
polymerases	I-GENE
of	I-GENE
trypanosomes	I-GENE
,	O
we	O
have	O
cloned	O
,	O
sequenced	O
and	O
examined	O
the	O
expression	O
of	O
the	O
Trypanosoma	O
(	O
Trypanozoon	O
)	O
brucei	O
brucei	O
gene	O
that	O
encodes	O
the	O
DNA	B-GENE
polymerase	I-GENE
alpha	I-GENE
catalytic	I-GENE
core	I-GENE
(	O
pol	B-GENE
alpha	I-GENE
)	O
.	O


Hence	O
,	O
the	O
uPA	B-GENE
promoter	I-GENE
contains	O
multiple	O
weak	O
cis	O
-	O
acting	O
elements	O
distributed	O
over	O
7	O
.	O
0	O
kb	O
5	O
'	O
to	O
the	O
translation	O
start	O
site	O
.	O


12	O
-	O
O	O
-	O
Tetradecanoylphorbol	O
13	O
-	O
acetate	O
was	O
found	O
to	O
inhibit	O
rapidly	O
and	O
potently	O
the	O
expression	O
of	O
mRNAs	O
coding	O
for	O
the	O
myogenic	O
regulators	O
CMD1	B-GENE
and	O
myogenin	B-GENE
.	O


The	O
mRNA	O
identified	O
in	O
both	O
human	O
and	O
rat	O
cells	O
with	O
the	O
human	B-GENE
clathrin	I-GENE
clone	O
revealed	O
transcripts	O
of	O
approximately	O
6	O
.	O
5	O
kb	O
,	O
which	O
is	O
consistent	O
with	O
the	O
predicted	O
180	O
kDa	O
molecular	O
weight	O
of	O
the	O
clathrin	B-GENE
heavy	I-GENE
chain	I-GENE
.	O


A	O
method	O
is	O
described	O
for	O
detecting	O
targeted	O
events	O
at	O
the	O
mu	B-GENE
heavy	I-GENE
chain	I-GENE
gene	I-GENE
which	O
relies	O
on	O
co	O
-	O
conversion	O
(	O
or	O
co	O
-	O
exchange	O
)	O
of	O
a	O
point	O
mutation	O
with	O
a	O
selectable	O
marker	O
contained	O
on	O
a	O
replacement	O
vector	O
.	O


Two	O
potential	O
regulatory	O
sequences	O
for	O
DNA	O
binding	O
proteins	O
were	O
found	O
in	O
the	O
non	O
-	O
coding	O
5	O
'	O
region	O
:	O
a	O
HAP2	B-GENE
/	O
HAP3	B-GENE
consensus	O
recognition	O
sequence	O
at	O
nucleotide	O
-	O
154	O
and	O
a	O
BAF1	B-GENE
consensus	I-GENE
recognition	I-GENE
sequence	I-GENE
at	O
nucleotide	O
-	O
136	O
.	O


A	O
330	O
-	O
kb	O
YAC	O
,	O
A148A7	O
,	O
spanned	O
from	O
the	O
HLA	B-GENE
-	O
DQA1	B-GENE
locus	O
through	O
the	O
Y3	B-GENE
/	O
Ring	B-GENE
4	I-GENE
locus	O
and	O
extended	O
at	O
least	O
130	O
kb	O
centromeric	O
of	O
YAC	O
B1D12	O
.	O


First	O
,	O
the	O
finding	O
of	O
a	O
monomeric	O
Alu	B-GENE
family	O
repeat	O
at	O
the	O
junction	O
between	O
nonhomology	O
block	O
I	O
and	O
homology	O
block	O
Y	O
of	O
the	O
alpha	B-GENE
2	I-GENE
gene	I-GENE
-	I-GENE
containing	I-GENE
unit	I-GENE
in	I-GENE
rhesus	I-GENE
macaque	I-GENE
suggests	O
that	O
the	O
dimeric	O
Alu	B-GENE
family	O
repeat	O
,	O
Alu	B-GENE
3	I-GENE
,	O
at	O
the	O
orthologous	O
position	O
in	O
human	O
was	O
generated	O
by	O
insertion	O
of	O
a	O
monomeric	O
Alu	B-GENE
family	O
repeat	O
into	O
the	O
3	O
'	O
end	O
of	O
another	O
preexisting	O
Alu	B-GENE
family	O
repeat	O
.	O


Ten	O
out	O
of	O
10	O
patients	O
with	O
progressive	O
disease	O
had	O
mast	O
cells	O
greater	O
than	O
or	O
equal	O
to	O
0	O
.	O
5	O
%	O
,	O
hyaluronan	O
greater	O
than	O
or	O
equal	O
to	O
50	O
micrograms	O
.	O
l	O
-	O
1	O
and	O
fibronectin	B-GENE
greater	O
than	O
or	O
equal	O
to	O
350	O
micrograms	O
.	O
l	O
-	O
1	O
compared	O
to	O
eight	O
out	O
of	O
41	O
patients	O
with	O
stable	O
or	O
regressive	O
disease	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


The	O
effects	O
of	O
contrast	O
media	O
on	O
coagulation	B-GENE
factor	I-GENE
XII	I-GENE
.	O


In	O
the	O
present	O
study	O
,	O
we	O
identified	O
a	O
strong	O
positive	O
cis	O
-	O
regulatory	O
element	O
at	O
-	O
70	O
bp	O
to	O
-	O
75	O
bp	O
in	O
the	O
LpS1	B-GENE
beta	I-GENE
promoter	I-GENE
with	O
the	O
sequence	O
(	O
G	O
)	O
6	O
and	O
a	O
similar	O
,	O
more	O
distal	O
cis	O
-	O
element	O
at	O
-	O
721	O
bp	O
to	O
-	O
726	O
bp	O
.	O


The	O
12S	B-GENE
E1A	I-GENE
product	I-GENE
does	O
not	O
activate	O
a	O
TRE	O
sequence	O
,	O
but	O
cotransfection	O
with	O
c	B-GENE
-	I-GENE
jun	I-GENE
circumvents	O
this	O
lack	O
of	O
stimulation	O
.	O


The	O
pp90rsk	B-GENE
-	I-GENE
protein	I-GENE
kinase	I-GENE
activity	O
(	O
referred	O
to	O
as	O
rsk	B-GENE
-	I-GENE
kinase	I-GENE
)	O
is	O
also	O
not	O
related	O
to	O
cofactor	O
-	O
dependent	O
signal	O
transducing	O
protein	O
kinases	O
such	O
as	O
the	O
cyclic	B-GENE
AMP	I-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinases	I-GENE
,	O
members	O
of	O
the	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
family	I-GENE
,	O
or	O
other	O
Ca2	B-GENE
(	I-GENE
+	I-GENE
)	I-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinases	I-GENE
.	O


Furthermore	O
,	O
the	O
UvrA	B-GENE
protein	I-GENE
interacts	O
with	O
the	O
UvrB	B-GENE
protein	I-GENE
to	O
modulate	O
its	O
activities	O
,	O
both	O
in	O
solution	O
and	O
in	O
association	O
with	O
DNA	O
,	O
where	O
the	O
UvrAB	B-GENE
complex	I-GENE
possesses	O
a	O
helicase	B-GENE
activity	O
.	O


Southwestern	O
blot	O
analysis	O
demonstrated	O
that	O
this	O
phosphoprotein	O
can	O
bind	O
the	O
kappa	B-GENE
B	I-GENE
element	I-GENE
directly	O
and	O
specifically	O
.	O


Imaging	O
of	O
D2	B-GENE
dopamine	I-GENE
receptor	I-GENE


The	O
murine	B-GENE
Mov	I-GENE
-	I-GENE
34	I-GENE
gene	I-GENE
:	O
full	O
-	O
length	O
cDNA	O
and	O
genomic	O
organization	O
.	O


When	O
transfected	O
into	O
Drosophila	O
SL	O
-	O
2	O
cells	O
,	O
pCAT	O
plasmid	O
containing	O
2	O
,	O
090	O
bp	O
of	O
5	O
'	O
-	O
flanking	O
region	O
shows	O
a	O
3	O
.	O
0	O
-	O
to	O
3	O
.	O
5	O
-	O
fold	O
increase	O
in	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
activity	O
after	O
induction	O
with	O
retinoic	O
acid	O
and	O
/	O
or	O
8	O
-	O
bromo	O
-	O
cAMP	O
.	O


The	O
N	O
-	O
terminus	O
of	O
another	O
open	O
reading	O
frame	O
was	O
found	O
3	O
'	O
from	O
nifA	B-GENE
and	O
tentatively	O
identified	O
as	O
nifB	B-GENE
by	O
amino	O
acid	O
sequence	O
comparison	O
.	O


Chagas	O
'	O
disease	O
,	O
visceral	O
leishmaniasis	O
,	O
anti	B-GENE
-	I-GENE
nuclear	I-GENE
factor	I-GENE
,	O
schistosomiasis	O
,	O
rheumatoid	B-GENE
factor	I-GENE
and	O
normal	O
controls	O
.	O


A	O
larger	O
region	O
upstream	O
of	O
human	B-GENE
CMV	I-GENE
dbp	I-GENE
also	O
mediated	O
replication	O
in	O
transient	O
assays	O
.	O


This	O
result	O
suggests	O
that	O
phosphorylation	O
of	O
Thr	O
14	O
and	O
/	O
or	O
Tyr	O
15	O
inhibits	O
p34cdc2	B-GENE
kinase	I-GENE
activity	O
,	O
in	O
line	O
with	O
the	O
location	O
of	O
these	O
residues	O
within	O
the	O
putative	O
ATP	O
binding	O
site	O
of	O
the	O
kinase	O
.	O


The	O
findings	O
are	O
compatible	O
with	O
the	O
idea	O
that	O
the	O
genes	O
encoding	O
PDGF	B-GENE
receptors	I-GENE
in	O
glioma	O
cells	O
are	O
regulated	O
in	O
concert	O
with	O
other	O
genes	O
,	O
the	O
expression	O
of	O
which	O
may	O
reflect	O
the	O
developmental	O
program	O
of	O
normal	O
glia	O
cell	O
lineages	O
.	O


Suggestive	O
evidence	O
was	O
obtained	O
that	O
cstA	B-GENE
is	O
involved	O
in	O
peptide	O
utilization	O
.	O


Heterodimers	O
of	O
myogenin	B-GENE
and	O
E12	B-GENE
(	O
or	O
MyoD	B-GENE
and	O
E12	B-GENE
)	O
specifically	O
bound	O
a	O
restriction	O
fragment	O
extending	O
from	O
-	O
200	O
to	O
-	O
103	O
relative	O
to	O
the	O
start	O
of	O
cardiac	B-GENE
alpha	I-GENE
-	I-GENE
actin	I-GENE
transcription	O
.	O


The	O
effects	O
of	O
c	B-GENE
-	I-GENE
myc	I-GENE
were	O
further	O
dissected	O
by	O
showing	O
that	O
c	B-GENE
-	I-GENE
myc	I-GENE
can	O
inhibit	O
differentiation	O
independently	O
of	O
Id	B-GENE
,	O
a	O
negative	O
regulator	O
of	O
muscle	O
differentiation	O
.	O


The	O
promoter	O
activity	O
of	O
the	O
gene	B-GENE
encoding	I-GENE
Alzheimer	I-GENE
beta	I-GENE
-	I-GENE
amyloid	I-GENE
precursor	I-GENE
protein	I-GENE
(	O
APP	B-GENE
)	O
is	O
regulated	O
by	O
two	O
blocks	O
of	O
upstream	O
sequences	O
.	O


Premature	O
initiation	O
of	O
mitosis	O
in	O
yeast	O
lacking	O
RCC1	B-GENE
or	O
an	O
interacting	O
GTPase	B-GENE
.	O


Space	O
limitations	O
prevent	O
an	O
exhaustive	O
review	O
of	O
all	O
biologic	O
pharmaceuticals	O
,	O
such	O
as	O
tissue	B-GENE
plasminogen	I-GENE
activating	I-GENE
substance	I-GENE
,	O
hormones	O
(	O
e	O
.	O
g	O
.	O
,	O
thyroid	O
,	O
insulin	B-GENE
,	O
growth	B-GENE
hormone	I-GENE
,	O
erythropoietin	B-GENE
)	O
,	O
clotting	O
factors	O
,	O
and	O
blood	O
products	O
.	O


The	O
various	O
forms	O
of	O
sickle	O
cell	O
disease	O
share	O
the	O
common	O
feature	O
of	O
an	O
abnormal	O
globin	B-GENE
chain	I-GENE
that	O
,	O
under	O
certain	O
conditions	O
such	O
as	O
hypoxia	O
,	O
results	O
in	O
the	O
sickling	O
of	O
red	O
blood	O
cells	O
and	O
obstruction	O
of	O
blood	O
vessels	O
.	O


Human	B-GENE
immunodeficiency	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
(	I-GENE
HIV	I-GENE
-	I-GENE
1	I-GENE
)	I-GENE
IN	I-GENE
,	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
was	O
purified	O
to	O
near	O
homogeneity	O
.	O


Analysis	O
of	O
viral	O
mutants	O
in	O
vivo	O
demonstrated	O
that	O
the	O
NFIII	B-GENE
/	O
OCT	B-GENE
-	I-GENE
1	I-GENE
binding	O
site	O
and	O
a	O
conserved	O
ATF	B-GENE
motif	I-GENE
were	O
important	O
for	O
efficient	O
viral	O
growth	O
.	O


This	O
indicates	O
that	O
under	O
certain	O
experimental	O
conditions	O
cdc2	B-GENE
/	O
p58	B-GENE
and	O
cdc2	B-GENE
/	O
p62	B-GENE
may	O
express	O
some	O
differences	O
in	O
their	O
catalytic	O
activity	O
.	O


The	O
enzymatic	O
response	O
of	O
neutrophils	O
and	O
monocytes	O
was	O
similar	O
although	O
the	O
magnitude	O
of	O
the	O
NADPH	B-GENE
oxidase	I-GENE
activity	O
was	O
significantly	O
higher	O
in	O
neutrophils	O
than	O
in	O
monocytes	O
.	O


All	O
members	O
are	O
also	O
capable	O
of	O
activating	O
in	O
vivo	O
transcription	O
from	O
promoters	O
that	O
contain	O
a	O
C	B-GENE
/	I-GENE
EBP	I-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
.	O


POU	B-GENE
-	O
specific	O
and	O
POU	B-GENE
-	O
homeo	O
domains	O
of	O
Oct3	B-GENE
were	O
produced	O
in	O
Echerichia	O
coli	O
for	O
characterization	O
of	O
DNA	O
binding	O
to	O
the	O
octamer	O
sequence	O
.	O


Determinants	O
of	O
recurrent	O
ischaemia	O
and	O
revascularisation	O
procedures	O
after	O
thrombolysis	O
with	O
recombinant	O
tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
in	O
primary	O
coronary	O
occlusion	O
.	O


Therefore	O
,	O
the	O
rbcL	B-GENE
-	O
rbcS	B-GENE
locus	O
seems	O
to	O
be	O
barely	O
expressed	O
under	O
a	O
standard	O
condition	O
for	O
photoautotrophic	O
growth	O
.	O


Sequence	O
requirements	O
for	O
premature	O
transcription	O
arrest	O
within	O
the	O
first	O
intron	O
of	O
the	O
mouse	B-GENE
c	I-GENE
-	I-GENE
fos	I-GENE
gene	I-GENE
.	O


If	O
this	O
is	O
the	O
case	O
,	O
identification	O
and	O
characterization	O
of	O
transcripts	O
from	O
the	O
Ig	B-GENE
loci	I-GENE
should	O
permit	O
a	O
better	O
understanding	O
of	O
the	O
gene	O
rearrangement	O
process	O
.	O


Transcription	O
of	O
the	O
metH	B-GENE
gene	I-GENE
in	I-GENE
Salmonella	I-GENE
typhimurium	I-GENE
and	I-GENE
Escherichia	I-GENE
coli	I-GENE
is	O
positively	O
regulated	O
by	O
the	O
metR	B-GENE
gene	I-GENE
product	I-GENE
,	O
a	O
DNA	O
binding	O
protein	O
.	O


Additionally	O
,	O
I	B-GENE
kappa	I-GENE
B	I-GENE
beta	I-GENE
,	O
but	O
not	O
I	B-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
,	O
also	O
prevented	O
the	O
binding	O
of	O
Rel	B-GENE
to	O
the	O
kappa	B-GENE
B	I-GENE
site	I-GENE
.	O


Sequence	O
analysis	O
reveals	O
that	O
the	O
DNA	O
binding	O
domain	O
of	O
ILF	B-GENE
has	O
strong	O
homology	O
to	O
the	O
recently	O
described	O
fork	B-GENE
head	I-GENE
DNA	I-GENE
binding	I-GENE
domain	I-GENE
found	O
in	O
the	O
Drosophila	B-GENE
homeotic	I-GENE
protein	I-GENE
fork	I-GENE
head	I-GENE
and	O
a	O
family	O
of	O
hepatocyte	B-GENE
nuclear	I-GENE
factors	I-GENE
,	O
HNF	B-GENE
-	I-GENE
3	I-GENE
.	O


The	O
structural	O
changes	O
in	O
intra	O
-	O
acinar	O
artery	O
manifested	O
mainly	O
by	O
an	O
increase	O
in	O
number	O
of	O
muscular	O
artery	O
resulting	O
from	O
muscularization	O
of	O
precursor	O
cells	O
(	O
pericytes	O
and	O
intermediate	O
cells	O
)	O
located	O
within	O
partially	O
muscular	O
and	O
nonmuscular	O
arterial	O
wall	O
to	O
smooth	O
muscle	O
cell	O
,	O
and	O
by	O
the	O
medial	O
wall	O
thickened	O
due	O
to	O
hypertrophy	O
and	O
hyperplasia	O
of	O
smooth	O
muscle	O
cells	O
as	O
well	O
as	O
accumulation	O
of	O
a	O
large	O
amount	O
of	O
collagen	B-GENE
,	O
especially	O
the	O
type	B-GENE
1	I-GENE
collagen	I-GENE
.	O


Lipoprotein	B-GENE
lipase	I-GENE
(	O
LPL	B-GENE
)	O
,	O
a	O
key	O
enzyme	O
in	O
normal	O
lipoprotein	O
metabolism	O
,	O
has	O
a	O
complex	O
pattern	O
of	O
regulation	O
and	O
tissue	O
-	O
specific	O
expression	O
.	O


We	O
examined	O
the	O
binding	O
of	O
purified	O
T3	B-GENE
receptor	I-GENE
alpha	I-GENE
(	O
T3R	B-GENE
alpha	I-GENE
)	O
,	O
overexpressed	O
in	O
Escherichia	O
coli	O
,	O
to	O
wild	O
-	O
type	O
and	O
up	O
and	O
down	O
mutations	O
of	O
the	O
rGH	B-GENE
T3RE	B-GENE
to	O
evaluate	O
whether	O
transcriptional	O
potency	O
correlates	O
with	O
changes	O
in	O
T3R	B-GENE
binding	O
.	O


Position	O
22	O
is	O
an	O
isoleucine	O
in	O
the	O
complete	B-GENE
SsoL12	I-GENE
protein	I-GENE
sequence	I-GENE
,	O
coded	O
by	O
an	O
AUA	O
codon	O
.	O


In	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
copper	O
levels	O
exert	O
some	O
control	O
over	O
the	O
level	O
of	O
SOD1	B-GENE
expression	O
.	O


Twenty	O
-	O
four	O
hours	O
later	O
,	O
the	O
animals	O
were	O
randomized	O
to	O
subretinal	O
treatment	O
with	O
2	O
.	O
5	O
micrograms	O
of	O
tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
or	O
a	O
similar	O
volume	O
of	O
physiologic	O
saline	O
.	O


The	O
effect	O
of	O
salmon	B-GENE
calcitonin	I-GENE
nasal	O
spray	O
in	O
women	O
with	O
established	O
osteoporosis	O
has	O
also	O
been	O
studied	O
.	O


We	O
conclude	O
that	O
solidification	O
could	O
occur	O
in	O
all	O
feeds	O
containing	O
casein	B-GENE
and	O
that	O
alternative	O
feeds	O
should	O
be	O
considered	O
in	O
patients	O
with	O
increased	O
gastric	O
acidity	O
.	O


Heterogeneous	O
electron	O
transfer	O
of	O
cytochrome	B-GENE
c	I-GENE
facilitated	O
by	O
polypyrrole	O
and	O
methylene	O
blue	O
polypyrrole	O
film	O
modified	O
electrodes	O
.	O


The	O
1489	O
-	O
base	O
pair	O
EFIA	B-GENE
cDNA	O
encodes	O
a	O
322	O
-	O
amino	O
acid	O
protein	O
which	O
is	O
nearly	O
identical	O
to	O
two	O
previously	O
described	O
human	O
DNA	O
binding	O
proteins	O
.	O


The	O
coding	O
sequence	O
for	O
a	O
260	O
-	O
amino	O
-	O
acid	O
residue	O
polypeptide	O
was	O
interrupted	O
by	O
a	O
single	O
short	O
intron	O
of	O
60	O
base	O
pairs	O
(	O
bp	O
)	O
,	O
and	O
about	O
70	O
%	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
Drosophila	B-GENE
PCNA	I-GENE
was	O
identical	O
to	O
the	O
rat	O
and	O
human	B-GENE
PCNA	I-GENE
polypeptides	I-GENE
,	O
with	O
conserved	O
unique	O
repeats	O
of	O
leucine	O
in	O
the	O
C	O
-	O
terminal	O
region	O
.	O


Translational	O
fusions	O
of	O
the	O
aroF	B-GENE
regulatory	I-GENE
regions	I-GENE
to	O
lacZ	B-GENE
were	O
constructed	O
and	O
then	O
introduced	O
in	O
single	O
copy	O
into	O
the	O
E	O
.	O
coli	O
chromosome	O
.	O
beta	B-GENE
-	I-GENE
Galactosidase	I-GENE
assays	O
for	O
tyrR	O
-	O
mediated	O
regulation	O
of	O
aroF	B-GENE
-	O
lacZ	B-GENE
expression	O
revealed	O
that	O
the	O
E	B-GENE
.	I-GENE
coli	I-GENE
TyrR	I-GENE
repressor	I-GENE
apparently	O
recognizes	O
the	O
operators	O
of	O
both	O
organisms	O
with	O
about	O
equal	O
efficiency	O
.	O


A	O
high	O
-	O
frequency	O
restriction	O
fragment	O
length	O
polymorphism	O
was	O
evident	O
in	O
the	O
DNA	O
from	O
29	O
unrelated	O
individuals	O
using	O
the	O
enzyme	O
BglII	B-GENE
.	O


Judicious	O
use	O
of	O
laboratory	O
testing	O
,	O
including	O
monitoring	O
of	O
CD4	B-GENE
cell	O
counts	O
,	O
is	O
recommended	O
.	O


Characterization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
growth	O
-	O
regulated	O
Syrian	B-GENE
hamster	I-GENE
CAD	I-GENE
gene	I-GENE
.	O


Cloning	O
,	O
expression	O
,	O
and	O
nucleotide	O
sequence	O
of	O
rat	B-GENE
liver	I-GENE
sterol	I-GENE
carrier	I-GENE
protein	I-GENE
2	I-GENE
cDNAs	I-GENE
.	O


Induction	O
requires	O
the	O
ACE1	B-GENE
gene	I-GENE
product	I-GENE
,	O
which	O
binds	O
to	O
specific	O
sites	O
in	O
the	O
promoter	O
region	O
of	O
the	O
CUP1	B-GENE
gene	I-GENE
.	O


The	O
sequence	O
of	O
four	O
clones	O
was	O
sufficient	O
to	O
construct	O
a	O
3018	B-GENE
-	I-GENE
bp	I-GENE
BAL	I-GENE
cDNA	I-GENE
structure	O
.	O


The	O
results	O
strengthen	O
the	O
conclusion	O
that	O
predominantly	O
dynamic	O
activity	O
increases	O
the	O
G4	B-GENE
content	O
of	O
mature	O
innervated	O
fast	O
muscles	O
.	O


Nucleotide	O
sequence	O
analysis	O
of	O
the	O
Pseudomonas	B-GENE
putida	I-GENE
PpG7	I-GENE
salicylate	I-GENE
hydroxylase	I-GENE
gene	I-GENE
(	O
nahG	B-GENE
)	O
and	O
its	O
3	O
'	O
-	O
flanking	O
region	O
.	O


All	O
six	O
ARF	B-GENE
cDNAs	I-GENE
are	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
other	O
approximately	O
20	B-GENE
-	I-GENE
kDa	I-GENE
guanine	I-GENE
nucleotide	I-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
.	O


DNA	O
from	O
PCR	O
was	O
labeled	O
and	O
used	O
to	O
isolate	O
several	O
lambda	O
gt11	O
cDNA	O
clones	O
,	O
including	O
one	O
full	O
-	O
length	O
one	O
(	O
Dd	B-GENE
kinase	I-GENE
-	I-GENE
2	I-GENE
)	O
.	O


The	O
cdr1	B-GENE
sequence	I-GENE
includes	O
an	O
additional	O
237	O
amino	O
acids	O
of	O
the	O
contiguous	O
fragment	O
and	O
encodes	O
a	O
product	O
of	O
predicted	O
Mr	O
67	O
,	O
000	O
.	O


Despite	O
the	O
small	O
number	O
of	O
patients	O
,	O
on	O
the	O
basis	O
of	O
this	O
report	O
,	O
we	O
can	O
confirm	O
that	O
1	O
.	O
5	O
MU	O
/	O
day	O
of	O
alpha	B-GENE
-	I-GENE
IFN	I-GENE
is	O
an	O
adequate	O
treatment	O
for	O
patients	O
with	O
hairy	O
cell	O
leukemia	O
.	O


Occupational	O
asthma	O
and	O
rhinoconjunctivitis	O
from	O
inhalation	O
of	O
crystalline	O
bovine	B-GENE
serum	I-GENE
albumin	I-GENE
powder	O
.	O


A	O
dose	O
of	O
3	O
and	O
6	O
micrograms	O
/	O
kg	O
/	O
day	O
GM	B-GENE
-	I-GENE
CSF	I-GENE
reduces	O
the	O
severity	O
of	O
neutropenia	O
and	O
thrombocytopenia	O
after	O
carboplatin	O
-	O
cyclophosphamide	O
chemotherapy	O
,	O
which	O
may	O
lead	O
to	O
more	O
effective	O
chemotherapy	O
for	O
ovarian	O
cancer	O
in	O
the	O
future	O
.	O


Biochemical	O
analysis	O
demonstrates	O
that	O
the	O
BJ1	B-GENE
protein	I-GENE
is	O
associated	O
with	O
nucleosomes	O
and	O
is	O
released	O
from	O
chromatin	O
by	O
agents	O
which	O
intercalate	O
into	O
DNA	O
,	O
as	O
previously	O
shown	O
for	O
the	O
high	B-GENE
mobility	I-GENE
group	I-GENE
proteins	I-GENE
(	O
HMGs	B-GENE
)	O
.	O


The	O
human	B-GENE
immunodeficiency	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
(	I-GENE
HIV	I-GENE
-	I-GENE
1	I-GENE
)	I-GENE
Rev	I-GENE
protein	I-GENE
is	O
a	O
positive	O
posttranscriptional	O
regulator	O
of	O
viral	O
structural	O
gene	O
expression	O
and	O
essential	O
for	O
virus	O
replication	O
.	O


Temporal	O
control	O
of	O
GUS	B-GENE
expression	O
was	O
found	O
to	O
involve	O
two	O
negative	O
regulatory	O
sequences	O
,	O
NRS1	O
(	O
-	O
391	O
to	O
-	O
295	O
)	O
and	O
NRS2	O
(	O
-	O
518	O
to	O
-	O
418	O
)	O
,	O
as	O
well	O
as	O
the	O
positive	O
domain	O
UAS1	O
.	O


In	O
most	O
cases	O
,	O
DR4	B-GENE
-	O
homozygous	O
,	O
DRB1	B-GENE
-	O
heterozygous	O
individuals	O
could	O
be	O
genotyped	O
with	O
the	O
panel	O
of	O
probes	O
.	O


Polymerase	O
chain	O
reaction	O
analysis	O
of	O
ETS1	B-GENE
cDNA	I-GENE
identified	O
several	O
amplified	O
products	O
,	O
indicating	O
alternative	O
splicing	O
.	O


To	O
test	O
promotor	O
function	O
,	O
chimeric	O
genes	O
were	O
constructed	O
linking	O
fragments	O
of	O
chicken	O
IGF	B-GENE
-	I-GENE
I	I-GENE
5	O
'	O
-	O
flanking	O
DNA	O
to	O
a	O
promoterless	O
reporter	O
plasmid	O
.	O


The	O
alpha	B-GENE
4	I-GENE
gene	I-GENE
5	O
'	O
flanking	O
region	O
acted	O
as	O
a	O
promoter	O
in	O
transfection	O
assays	O
.	O


Two	O
homologues	O
of	O
the	O
rhombotin	B-GENE
gene	I-GENE
have	O
now	O
been	O
isolated	O
.	O


The	O
gcd2	B-GENE
-	I-GENE
503	I-GENE
mutation	O
also	O
results	O
in	O
polysome	O
runoff	O
,	O
accumulation	O
of	O
inactive	O
80S	B-GENE
ribosomal	I-GENE
couples	I-GENE
,	O
and	O
accumulation	O
of	O
at	O
least	O
one	O
of	O
the	O
subunits	O
of	O
the	O
general	B-GENE
translation	I-GENE
initiation	I-GENE
factor	I-GENE
2	I-GENE
(	O
eIF	B-GENE
-	I-GENE
2	I-GENE
alpha	I-GENE
)	O
in	O
43S	B-GENE
-	O
48S	B-GENE
particles	O
following	O
a	O
shift	O
to	O
the	O
restrictive	O
temperature	O
.	O


Using	O
the	O
polymerase	O
chain	O
reaction	O
,	O
we	O
analyzed	O
the	O
U6	B-GENE
RNA	I-GENE
genes	I-GENE
of	O
52	O
organisms	O
.	O


To	O
determine	O
whether	O
mononuclear	O
cell	O
secretory	O
products	O
contribute	O
to	O
the	O
changes	O
in	O
bone	O
turnover	O
that	O
characterize	O
the	O
development	O
of	O
postmenopausal	O
osteoporosis	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
oophorectomy	O
and	O
subsequent	O
estrogen	O
replacement	O
on	O
the	O
spontaneous	O
secretion	O
of	O
interleukin	B-GENE
1	I-GENE
(	O
IL	B-GENE
-	I-GENE
1	I-GENE
)	O
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha	I-GENE
(	O
TNF	B-GENE
-	I-GENE
alpha	I-GENE
)	O
and	O
on	O
the	O
phytohemagglutinin	B-GENE
A	I-GENE
-	O
induced	O
secretion	O
of	O
granulocyte	B-GENE
-	I-GENE
macrophage	I-GENE
colony	I-GENE
-	I-GENE
stimulating	I-GENE
factor	I-GENE
(	O
GM	B-GENE
-	I-GENE
CSF	I-GENE
)	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O


Some	O
of	O
the	O
PCR	O
products	O
contained	O
mutations	O
in	O
ATG1	B-GENE
and	O
/	O
or	O
ATG2	B-GENE
.	O


These	O
observations	O
,	O
together	O
with	O
the	O
occurrence	O
of	O
putative	O
4	O
'	O
-	O
phosphopantetheine	O
-	O
attachment	O
sites	O
and	O
a	O
putative	O
thioesterase	B-GENE
site	I-GENE
,	O
are	O
discussed	O
with	O
reference	O
to	O
the	O
reaction	O
sequence	O
leading	O
to	O
production	O
of	O
the	O
ACV	B-GENE
tripeptide	I-GENE
.	O


Very	O
small	O
deletions	O
within	O
the	O
conserved	O
region	O
completely	O
abolished	O
transforming	O
activity	O
of	O
dbl	B-GENE
,	O
while	O
extensive	O
deletion	O
outside	O
of	O
this	O
region	O
had	O
no	O
effect	O
.	O


We	O
also	O
present	O
evidence	O
for	O
a	O
negative	O
regulatory	O
element	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
Mlu	B-GENE
I	I-GENE
upstream	I-GENE
activation	I-GENE
sequence	I-GENE
.	O


Furthermore	O
,	O
plasma	O
fibrinogen	B-GENE
levels	O
increased	O
by	O
a	O
mean	O
of	O
17	O
.	O
6	O
%	O
,	O
a	O
potentially	O
adverse	O
effect	O
of	O
gemfibrozil	O
that	O
has	O
not	O
been	O
previously	O
reported	O
.	O


To	O
investigate	O
the	O
regulation	O
of	O
Spec	B-GENE
gene	I-GENE
activity	O
,	O
the	O
region	O
around	O
the	O
Spec1	B-GENE
transcriptional	I-GENE
initiation	I-GENE
site	I-GENE
was	O
analyzed	O
for	O
sites	O
of	O
protein	O
-	O
DNA	O
interaction	O
.	O


A	O
new	O
method	O
for	O
the	O
in	O
vitro	O
transfer	O
of	O
delayed	O
hypersensitivity	O
by	O
dialysed	O
transfer	B-GENE
factor	I-GENE
.	O


Diagnostic	O
value	O
of	O
adenosine	B-GENE
deaminase	I-GENE
activity	O
in	O
tuberculous	O
effusions	O
.	O


An	O
evolutionary	O
comparison	O
of	O
amino	O
acid	O
sequences	O
of	O
34	O
HSP70	B-GENE
proteins	I-GENE
from	O
17	O
species	O
suggests	O
that	O
BiP	B-GENE
genes	I-GENE
share	O
a	O
common	O
ancestor	O
,	O
which	O
diverged	O
from	O
other	O
HSP70	B-GENE
genes	I-GENE
near	O
the	O
time	O
when	O
eukaryotes	O
first	O
appeared	O
.	O


However	O
,	O
overexpression	O
of	O
both	O
the	O
STE4	B-GENE
and	O
STE18	B-GENE
proteins	I-GENE
did	O
not	O
generate	O
a	O
stronger	O
pheromone	O
response	O
than	O
overexpression	O
of	O
STE4	B-GENE
in	O
the	O
presence	O
of	O
wild	O
-	O
type	O
levels	O
of	O
STE18	B-GENE
.	O


Sequencing	O
the	O
gene	O
for	O
an	O
imipenem	O
-	O
cefoxitin	O
-	O
hydrolyzing	O
enzyme	O
(	O
CfiA	B-GENE
)	O
from	O
Bacteroides	O
fragilis	O
TAL2480	O
reveals	O
strong	O
similarity	O
between	O
CfiA	B-GENE
and	O
Bacillus	B-GENE
cereus	I-GENE
beta	I-GENE
-	I-GENE
lactamase	I-GENE
II	I-GENE
.	O


The	O
cloned	O
HindIII	B-GENE
fragment	I-GENE
,	O
which	O
was	O
shown	O
by	O
DNA	O
sequence	O
analysis	O
to	O
encode	O
the	O
N	O
-	O
terminal	O
half	O
of	O
the	O
B	B-GENE
.	I-GENE
subtilis	I-GENE
IF2	I-GENE
protein	I-GENE
and	O
0	O
.	O
2	O
kb	O
of	O
upstream	O
flanking	O
sequence	O
,	O
was	O
utilized	O
as	O
a	O
homologous	O
probe	O
to	O
clone	O
an	O
overlapping	O
2	B-GENE
.	I-GENE
76	I-GENE
-	I-GENE
kb	I-GENE
ClaI	I-GENE
chromosomal	I-GENE
fragment	I-GENE
containing	O
the	O
entire	B-GENE
IF2	I-GENE
structural	I-GENE
gene	I-GENE
.	O


Expression	O
,	O
nucleotide	O
sequence	O
and	O
mutational	O
analysis	O
of	O
two	O
open	O
reading	O
frames	O
in	O
the	O
nif	B-GENE
gene	I-GENE
region	I-GENE
of	I-GENE
Anabaena	I-GENE
sp	I-GENE
.	I-GENE
strain	I-GENE
PCC7120	I-GENE
.	O


This	O
Mr	O
is	O
similar	O
to	O
those	O
of	O
the	O
purified	B-GENE
smg	I-GENE
p25A	I-GENE
GDI	I-GENE
estimated	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
sucrose	O
density	O
gradient	O
ultracentrifugation	O
,	O
which	O
are	O
about	O
54	O
,	O
000	O
and	O
65	O
,	O
000	O
,	O
respectively	O
.	O


Critical	O
residues	O
required	O
for	O
repression	O
are	O
located	O
within	O
the	O
C	O
-	O
terminal	O
27	O
amino	O
acids	O
of	O
c	B-GENE
-	I-GENE
Fos	I-GENE
,	O
since	O
v	B-GENE
-	I-GENE
Fos	I-GENE
and	O
C	O
-	O
terminal	O
truncations	O
of	O
c	B-GENE
-	I-GENE
Fos	I-GENE
did	O
not	O
down	O
regulate	O
.	O


In	O
this	O
paper	O
,	O
we	O
have	O
analyzed	O
the	O
structure	O
of	O
human	O
gene	O
for	O
Gx	B-GENE
alpha	I-GENE
,	O
which	O
spans	O
more	O
than	O
60	O
kilobases	O
.	O


In	O
addition	O
,	O
the	O
-	O
119	O
to	O
-	O
81	O
fragment	O
of	O
the	O
CCK	B-GENE
promoter	I-GENE
contains	O
a	O
transcriptional	O
enhancer	O
that	O
potentiates	O
the	O
transcription	O
from	O
the	O
herpes	O
simplex	O
virus	O
thymidine	B-GENE
kinase	I-GENE
promoter	I-GENE
in	O
a	O
position	O
-	O
and	O
orientation	O
-	O
independent	O
manner	O
.	O


The	O
NF1	B-GENE
locus	I-GENE
encodes	O
a	O
protein	O
functionally	O
related	O
to	O
mammalian	B-GENE
GAP	I-GENE
and	O
yeast	B-GENE
IRA	I-GENE
proteins	I-GENE
.	O


Disruption	O
of	O
ARF2	B-GENE
causes	O
no	O
detectable	O
phenotype	O
.	O


Human	O
recombinant	O
DNA	O
-	O
derived	O
antihemophilic	B-GENE
factor	I-GENE
(	O
factor	B-GENE
VIII	I-GENE
)	O
in	O
the	O
treatment	O
of	O
hemophilia	O
A	O
.	O
recombinant	O
Factor	B-GENE
VIII	I-GENE
Study	O
Group	O
.	O


Effects	O
of	O
a	O
selective	O
monoamine	B-GENE
oxidase	I-GENE
(	I-GENE
MAO	I-GENE
)	I-GENE
-	I-GENE
-	I-GENE
A	I-GENE
inhibitor	O
,	O
clorgyline	O
,	O
a	O
selective	O
MAO	B-GENE
-	I-GENE
B	I-GENE
inhibitor	O
,	O
deprenyl	O
,	O
and	O
a	O
non	O
-	O
selective	O
MAO	B-GENE
inhibitor	O
,	O
nialamide	O
,	O
were	O
investigated	O
on	O
footshock	O
-	O
induced	O
aggression	O
(	O
FIA	O
)	O
in	O
paired	O
rats	O
.	O


To	O
identify	O
structural	O
features	O
of	O
residues	O
flanking	O
the	O
c	O
-	O
region	O
that	O
influence	O
the	O
fidelity	O
and	O
efficiency	O
of	O
signal	O
peptidase	O
cleavage	O
as	O
well	O
as	O
co	O
-	O
translational	O
translocation	O
,	O
we	O
introduced	O
six	O
amino	O
acid	O
substitutions	O
into	O
the	O
COOH	O
terminus	O
of	O
the	O
hydrophobic	O
core	O
and	O
seven	O
substitutions	O
at	O
the	O
NH2	O
terminus	O
of	O
the	O
mature	O
region	O
(	O
the	O
+	O
1	O
position	O
)	O
of	O
a	O
model	O
eukaryotic	B-GENE
preprotein	I-GENE
-	I-GENE
human	I-GENE
pre	I-GENE
(	I-GENE
delta	I-GENE
pro	I-GENE
)	I-GENE
apoA	I-GENE
-	I-GENE
II	I-GENE
.	O


This	O
model	O
is	O
further	O
supported	O
by	O
binding	O
of	O
the	O
Fos	B-GENE
-	O
Jun	B-GENE
complex	O
at	O
an	O
AP	B-GENE
-	I-GENE
1	I-GENE
site	I-GENE
in	O
the	O
type	B-GENE
alpha	I-GENE
I	I-GENE
collagen	I-GENE
promoter	I-GENE
that	O
is	O
contiguous	O
with	O
,	O
but	O
not	O
overlapping	O
,	O
the	O
VDRE	O
.	O


PBSX	B-GENE
is	O
induced	O
by	O
agents	O
which	O
elicit	O
the	O
SOS	O
response	O
.	O


The	O
p36	B-GENE
gene	I-GENE
is	O
at	O
least	O
22	O
kb	O
in	O
length	O
and	O
has	O
a	O
coding	O
sequence	O
of	O
approximately	O
1	O
kb	O
,	O
representing	O
only	O
4	O
.	O
5	O
%	O
of	O
the	O
gene	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Northern	O
blot	O
analysis	O
indicates	O
that	O
AHA2	B-GENE
mRNA	I-GENE
relative	O
to	O
total	O
cellular	O
RNA	O
is	O
expressed	O
at	O
significantly	O
higher	O
levels	O
in	O
root	O
tissue	O
as	O
compared	O
with	O
shoot	O
tissue	O
.	O


The	O
3	O
'	O
stem	O
-	O
loop	O
is	O
highly	O
divergent	O
in	O
structure	O
among	O
species	O
and	O
lies	O
immediately	O
upstream	O
of	O
the	O
binding	O
site	O
for	O
Sm	B-GENE
proteins	I-GENE
.	O


The	O
deleted	O
nucleotide	O
sequence	O
corresponded	O
to	O
sequences	O
that	O
,	O
by	O
analogy	O
to	O
the	O
organization	O
of	O
the	O
type	B-GENE
I	I-GENE
collagen	I-GENE
genes	I-GENE
,	O
should	O
be	O
precisely	O
encoded	O
by	O
exon	O
41	O
of	O
the	O
COL3A1	B-GENE
gene	I-GENE
.	O


We	O
have	O
isolated	O
and	O
sequenced	O
the	O
gene	O
encoding	O
the	O
human	B-GENE
U1	I-GENE
-	I-GENE
70K	I-GENE
snRNP	I-GENE
protein	I-GENE
.	O


Cutaneous	O
necrosis	O
associated	O
with	O
protein	B-GENE
S	I-GENE
deficiency	O
.	O


These	O
data	O
strongly	O
implicate	O
the	O
normal	O
product	O
of	O
the	O
int	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
,	O
which	O
is	O
related	O
to	O
the	O
fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
family	I-GENE
,	O
as	O
a	O
contributory	O
factor	O
in	O
virally	O
induced	O
mammary	O
tumors	O
.	O


Whether	O
or	O
not	O
there	O
are	O
sequences	O
conferring	O
cAMP	O
responsiveness	O
which	O
are	O
common	O
both	O
to	O
P	B-GENE
-	I-GENE
450scc	I-GENE
and	O
the	O
other	O
steroidogenic	O
P	B-GENE
-	I-GENE
450	I-GENE
genes	I-GENE
remains	O
to	O
be	O
established	O
.	O


The	O
zta	B-GENE
transactivator	I-GENE
involved	O
in	O
induction	O
of	O
lytic	O
cycle	O
gene	O
expression	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
infected	O
lymphocytes	O
binds	O
to	O
both	O
AP	B-GENE
-	I-GENE
1	I-GENE
and	O
ZRE	B-GENE
sites	I-GENE
in	O
target	O
promoter	O
and	O
enhancer	O
regions	O
.	O


The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
destrin	B-GENE
is	O
165	O
residues	O
long	O
and	O
is	O
very	O
similar	O
(	O
71	O
%	O
identical	O
)	O
to	O
that	O
of	O
cofilin	B-GENE
,	O
a	O
widely	O
distributed	O
,	O
pH	O
-	O
sensitive	O
actin	B-GENE
-	O
modulating	O
protein	O
.	O


With	O
only	O
purified	O
T	B-GENE
antigen	I-GENE
in	O
the	O
presence	O
of	O
topoisomerase	B-GENE
I	I-GENE
to	O
unwind	O
purified	O
DNA	O
,	O
ori	O
-	O
auxiliary	O
sequences	O
strongly	O
facilitated	O
T	B-GENE
-	I-GENE
antigen	I-GENE
-	O
dependent	O
DNA	O
conformational	O
changes	O
consistent	O
with	O
melting	O
the	O
first	O
50	O
base	O
pairs	O
.	O


We	O
cloned	O
and	O
sequenced	O
the	O
cDNAs	O
against	O
genomic	O
RNA	O
and	O
mRNA	O
for	O
phosphoprotein	B-GENE
(	I-GENE
P	I-GENE
)	I-GENE
of	O
human	O
parainfluenza	O
type	O
2	O
virus	O
(	O
PIV	O
-	O
2	O
)	O
.	O
cDNA	O
clone	O
from	O
genomic	O
RNA	O
was	O
1439	O
nucleotides	O
in	O
length	O
excluding	O
poly	O
(	O
A	O
)	O
and	O
was	O
found	O
to	O
have	O
two	O
small	O
open	O
reading	O
frames	O
encoding	O
proteins	O
of	O
233	O
and	O
249	O
amino	O
acids	O
.	O


The	O
cDNA	O
sequence	O
has	O
an	O
813	O
-	O
bp	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
whose	O
predicted	O
amino	O
acid	O
sequence	O
is	O
97	O
.	O
6	O
%	O
identical	O
to	O
the	O
272	O
carboxy	O
-	O
terminal	O
amino	O
acids	O
of	O
the	O
human	B-GENE
ets	I-GENE
-	I-GENE
1	I-GENE
protein	I-GENE
.	O


To	O
characterize	O
the	O
O7	B-GENE
-	I-GENE
LPS	I-GENE
region	I-GENE
,	O
the	O
recombinant	O
cosmids	O
pJHCV31	O
and	O
pJHCV32	O
were	O
mutagenized	O
by	O
transposon	O
mutagenesis	O
with	O
Tn3HoHo1	B-GENE
,	O
which	O
carries	O
a	O
promoterless	O
lac	B-GENE
operon	I-GENE
and	O
can	O
therefore	O
generate	O
lacZ	B-GENE
transcriptional	O
fusions	O
with	O
target	O
DNA	O
sequences	O
.	O


Various	O
mutant	B-GENE
HN	I-GENE
genes	I-GENE
were	O
constructed	O
to	O
examine	O
the	O
role	O
of	O
residues	O
flanking	O
the	O
signal	O
-	O
anchor	O
domain	O
,	O
including	O
the	O
cytoplasmic	O
tail	O
,	O
on	O
assembly	O
and	O
intracellular	O
transport	O
of	O
the	O
HN	B-GENE
glycoprotein	I-GENE
.	O


Disruption	O
of	O
the	O
IRA2	B-GENE
gene	I-GENE
resulted	O
in	O
(	O
i	O
)	O
increased	O
sensitivity	O
to	O
heat	O
shock	O
and	O
nitrogen	O
starvation	O
,	O
(	O
ii	O
)	O
sporulation	O
defects	O
,	O
and	O
(	O
iii	O
)	O
suppression	O
of	O
the	O
lethality	O
of	O
the	O
cdc25	B-GENE
mutant	I-GENE
.	O


A	O
DNA	O
motif	O
related	O
to	O
the	O
cAMP	O
-	O
responsive	O
element	O
and	O
an	O
exon	B-GENE
-	I-GENE
located	I-GENE
activator	I-GENE
protein	I-GENE
-	I-GENE
2	I-GENE
binding	I-GENE
site	I-GENE
in	O
the	O
human	B-GENE
tissue	I-GENE
-	I-GENE
type	I-GENE
plasminogen	I-GENE
activator	I-GENE
gene	I-GENE
promoter	I-GENE
cooperate	O
in	O
basal	O
expression	O
and	O
convey	O
activation	O
by	O
phorbol	O
ester	O
and	O
cAMP	O
.	O


Transcription	O
of	O
the	O
first	O
operon	O
coding	O
for	O
m	O
-	O
xylene	O
-	O
degrading	O
enzymes	O
on	O
the	O
TOL	O
plasmid	O
of	O
Pseudomonas	O
putida	O
is	O
activated	O
by	O
the	O
xylR	B-GENE
gene	I-GENE
product	I-GENE
in	O
the	O
presence	O
of	O
m	O
-	O
xylene	O
.	O


We	O
show	O
also	O
that	O
RA	O
represses	O
the	O
transcriptional	O
activity	O
of	O
a	O
reporter	O
gene	O
containing	O
a	O
TPA	O
responding	O
AP1	B-GENE
binding	I-GENE
site	I-GENE
driving	O
the	O
HSV	B-GENE
tk	I-GENE
promoter	I-GENE
.	O


Moreover	O
,	O
radiolabeled	O
EFI	B-GENE
,	O
NF	B-GENE
-	I-GENE
Y	I-GENE
,	O
or	O
CBF	B-GENE
DNAs	I-GENE
give	O
rise	O
to	O
identical	O
gel	O
retardation	O
patterns	O
in	O
extracts	O
from	O
a	O
variety	O
of	O
different	O
cell	O
types	O
.	O


The	O
promoter	O
activity	O
was	O
measured	O
by	O
a	O
transient	O
expression	O
of	O
a	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
gene	O
connected	O
with	O
various	O
5	O
'	O
-	O
deletion	O
mutants	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
.	O


The	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
14DM	I-GENE
gene	I-GENE
,	O
encoding	O
cytochrome	B-GENE
P450	I-GENE
lanosterol	I-GENE
14	I-GENE
alpha	I-GENE
-	I-GENE
demethylase	I-GENE
(	O
14DM	B-GENE
)	O
,	O
was	O
overexpressed	O
in	O
various	O
S	O
.	O
cerevisiae	O
strains	O
under	O
the	O
control	O
of	O
three	O
strong	O
heterologous	O
yeast	O
transcription	O
promoters	O
(	O
pADC1	B-GENE
,	O
pGPD	B-GENE
,	O
pPHO5	B-GENE
)	O
and	O
under	O
the	O
control	O
of	O
its	O
own	O
promoter	O
.	O


The	O
ANB1	B-GENE
locus	I-GENE
of	O
Saccharomyces	O
cerevisiae	O
encodes	O
the	O
protein	B-GENE
synthesis	I-GENE
initiation	I-GENE
factor	I-GENE
eIF	I-GENE
-	I-GENE
4D	I-GENE
.	O


Specific	O
hyperimmune	B-GENE
globulins	I-GENE
to	O
pathogens	O
such	O
as	O
Haemophilus	O
influenzae	O
and	O
Streptococcus	O
pneumoniae	O
have	O
also	O
been	O
studied	O
.	O


Homozygous	O
individuals	O
usually	O
develop	O
purpura	O
fulminans	O
as	O
newborns	O
;	O
heterozygous	O
protein	B-GENE
C	I-GENE
-	O
deficient	O
individuals	O
are	O
at	O
increased	O
risk	O
for	O
venous	O
thrombosis	O
and	O
pulmonary	O
embolism	O
.	O


TREB7	B-GENE
and	O
TREB36	B-GENE
protected	O
all	O
three	O
repeats	O
of	O
the	O
21	O
bp	O
,	O
but	O
TREB5	B-GENE
protected	O
only	O
the	O
second	O
repeat	O
.	O


Since	O
general	B-GENE
regulatory	I-GENE
factor	I-GENE
I	I-GENE
(	O
GRFI	B-GENE
)	O
/	O
repressor	B-GENE
/	I-GENE
activator	I-GENE
site	I-GENE
binding	I-GENE
protein	I-GENE
1	I-GENE
(	O
RAP1	B-GENE
)	O
/	O
translation	B-GENE
upstream	I-GENE
factor	I-GENE
(	O
TUF	B-GENE
)	O
is	O
believed	O
to	O
be	O
an	O
activator	O
of	O
MAT	B-GENE
alpha	I-GENE
expression	O
,	O
we	O
examined	O
whether	O
PYK1	B-GENE
,	O
which	O
is	O
known	O
to	O
be	O
regulated	O
by	O
GRFI	B-GENE
/	O
RAP1	B-GENE
/	O
TUF	B-GENE
,	O
is	O
also	O
affected	O
by	O
the	O
gal11	B-GENE
mutation	I-GENE
.	O


In	O
vitro	O
transcription	O
extracts	O
from	O
ret1	B-GENE
-	I-GENE
1	I-GENE
cells	O
terminate	O
less	O
efficiently	O
at	O
weak	O
transcription	O
termination	O
signals	O
than	O
those	O
from	O
RET1	B-GENE
cells	O
,	O
using	O
a	O
variety	O
of	O
tRNA	O
templates	O
.	O


These	O
factors	O
belong	O
to	O
a	O
set	O
of	O
genetically	O
distinct	O
molecules	O
,	O
including	O
AP	B-GENE
-	I-GENE
4	I-GENE
and	O
MLTF	B-GENE
,	O
that	O
bind	O
to	O
the	O
CACCTGTC	O
motif	O
or	O
related	O
sequences	O
.	O


RNase	B-GENE
protection	O
assays	O
reveal	O
that	O
this	O
gene	O
,	O
unr	B-GENE
,	O
is	O
transcribed	O
in	O
the	O
same	O
direction	O
as	O
N	B-GENE
-	I-GENE
ras	I-GENE
and	O
that	O
its	O
3	O
'	O
end	O
is	O
located	O
just	O
130	O
base	O
pairs	O
away	O
from	O
the	O
point	O
at	O
which	O
N	B-GENE
-	I-GENE
ras	I-GENE
transcription	O
begins	O
.	O


The	O
juxtamembrane	O
region	O
of	O
the	O
insulin	B-GENE
receptor	I-GENE
(	I-GENE
IR	I-GENE
)	I-GENE
beta	I-GENE
-	I-GENE
subunit	I-GENE
contains	O
an	O
unphosphorylated	O
tyrosyl	O
residue	O
(	O
Tyr960	O
)	O
that	O
is	O
essential	O
for	O
insulin	B-GENE
-	O
stimulated	O
tyrosyl	O
phosphorylation	O
of	O
some	O
endogenous	O
substrates	O
and	O
certain	O
biological	O
responses	O
(	O
White	O
,	O
M	O
.	O
F	O
.	O
,	O
Livingston	O
,	O
J	O
.	O
N	O
.	O
,	O
Backer	O
,	O
J	O
.	O
M	O
.	O
,	O
Lauris	O
,	O
V	O
.	O
,	O
Dull	O
,	O
T	O
.	O
J	O
.	O
,	O
Ullrich	O
,	O
A	O
.	O
,	O
and	O
Kahn	O
,	O
C	O
.	O
R	O
.	O


This	O
gene	O
joins	O
the	O
group	O
of	O
genes	O
whose	O
members	O
are	O
rapidly	O
transcribed	O
in	O
response	O
to	O
insulin	B-GENE
and	O
other	O
mitogens	O
.	O


Homozygous	O
protein	B-GENE
C	I-GENE
(	O
PC	B-GENE
)	O
deficiency	O
is	O
reported	O
in	O
two	O
siblings	O
(	O
girl	O
and	O
boy	O
)	O
who	O
received	O
their	O
proper	O
diagnoses	O
at	O
the	O
ages	O
of	O
7	O
4	O
/	O
12	O
and	O
1	O
3	O
/	O
12	O
years	O
respectively	O
.	O


Within	O
this	O
sequence	O
the	O
MSAS	B-GENE
gene	I-GENE
was	O
identified	O
as	O
a	O
5322	O
-	O
bp	O
-	O
long	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
protein	O
of	O
1774	O
amino	O
acids	O
and	O
190	O
,	O
731	O
Da	O
molecular	O
mass	O
.	O


The	O
interrelation	O
of	O
the	O
levels	O
of	O
glucocorticoids	O
and	O
insulin	B-GENE
in	O
the	O
blood	O
of	O
irradiated	O
animals	O


Primer	O
extension	O
analysis	O
and	O
RNA	O
sequencing	O
demonstrates	O
that	O
the	O
transcription	O
start	O
point	O
of	O
rat	B-GENE
ODC	I-GENE
mRNA	I-GENE
is	O
located	O
303	O
nt	O
upstream	O
from	O
the	O
A	O
residue	O
in	O
the	O
start	O
codon	O
.	O


These	O
results	O
indicate	O
that	O
the	O
cis	O
-	O
regulatory	O
elements	O
required	O
for	O
developmental	O
control	O
of	O
the	O
HaG3	B-GENE
-	I-GENE
A	I-GENE
helianthinin	I-GENE
gene	I-GENE
are	O
located	O
in	O
a	O
2	O
.	O
4	O
kb	O
upstream	O
region	O
of	O
this	O
gene	O
.	O


Some	O
mutations	O
affected	O
Dhfr	B-GENE
in	O
a	O
qualitative	O
manner	O
,	O
such	O
as	O
by	O
changing	O
the	O
startpoint	O
of	O
one	O
of	O
the	O
major	O
Dhfr	B-GENE
transcripts	I-GENE
or	O
changing	O
the	O
relative	O
abundance	O
of	O
the	O
two	O
major	O
Dhfr	B-GENE
transcripts	I-GENE
.	O


As	O
in	O
mammals	O
,	O
considerable	O
nucleotide	O
diversity	O
was	O
observed	O
at	O
the	O
junctions	O
of	O
the	O
variable	O
,	O
diversity	O
,	O
and	O
joining	O
elements	O
in	O
chicken	B-GENE
TCR	I-GENE
beta	I-GENE
cDNAs	I-GENE
.	O


S6	B-GENE
kinase	I-GENE
activation	O
requires	O
displacement	O
of	O
this	O
inhibitory	O
segment	O
,	O
which	O
is	O
proposed	O
to	O
occur	O
consequent	O
to	O
its	O
multiple	O
phosphorylation	O
.	O


The	O
SUP44	B-GENE
suppressor	I-GENE
mutation	I-GENE
occurs	O
near	O
a	O
region	O
of	O
the	O
protein	O
that	O
corresponds	O
to	O
the	O
known	O
positions	O
of	O
alterations	O
in	O
E	B-GENE
.	I-GENE
coli	I-GENE
S5	I-GENE
ram	I-GENE
mutations	I-GENE
.	O


Results	O
have	O
surprisingly	O
revealed	O
the	O
presence	O
of	O
three	O
U14	B-GENE
snRNA	I-GENE
-	I-GENE
homologous	I-GENE
regions	I-GENE
positioned	O
within	O
introns	O
5	O
,	O
6	O
,	O
and	O
8	O
of	O
the	O
mouse	O
cognate	O
hsc70	B-GENE
heat	O
shock	O
gene	O
.	O


65	O
-	O
kilodalton	O
protein	O
phosphorylated	O
by	O
interleukin	B-GENE
2	I-GENE
stimulation	O
bears	O
two	O
putative	O
actin	B-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
and	O
two	O
calcium	O
-	O
binding	O
sites	O
.	O


Serum	O
Fibrin	B-GENE
Degradation	I-GENE
Products	I-GENE
(	O
FDP	B-GENE
)	O
were	O
determined	O
in	O
50	O
oral	O
cancer	O
patients	O
and	O
50	O
normal	O
individuals	O
prior	O
to	O
any	O
kind	O
of	O
treatment	O
.	O


The	O
mean	O
change	O
in	O
HbA1	B-GENE
,	O
adjusted	O
for	O
the	O
initial	O
value	O
,	O
was	O
-	O
0	O
.	O
4	O
%	O
in	O
the	O
experimental	O
and	O
+	O
0	O
.	O
5	O
%	O
in	O
the	O
control	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O


Effect	O
of	O
biliary	O
obstruction	O
and	O
cholangitis	O
on	O
serum	B-GENE
SPan	I-GENE
-	I-GENE
1	I-GENE
level	O


By	O
introducing	O
a	O
series	O
of	O
deletions	O
in	O
the	O
vimentin	B-GENE
promoter	O
,	O
we	O
further	O
restrict	O
these	O
sequences	O
to	O
30	O
base	O
pairs	O
,	O
located	O
between	O
241	O
and	O
210	O
base	O
pairs	O
upstream	O
of	O
the	O
mRNA	O
cap	O
site	O
.	O


All	O
89	O
participating	O
household	O
members	O
were	O
anti	B-GENE
-	I-GENE
HIV	I-GENE
seronegative	O
,	O
and	O
78	O
who	O
were	O
tested	O
were	O
serum	B-GENE
p24	I-GENE
antigen	I-GENE
negative	O
.	O


To	O
define	O
the	O
mechanism	O
responsible	O
for	O
the	O
loss	O
of	O
transcription	O
elongation	O
blockage	O
and	O
resulting	O
c	B-GENE
-	I-GENE
myc	I-GENE
deregulation	O
in	O
Burkitt	O
'	O
s	O
lymphoma	O
,	O
we	O
analyzed	O
transcription	O
patterns	O
after	O
transfer	O
of	O
normal	O
and	O
Burkitt	O
'	O
s	O
lymphoma	O
c	B-GENE
-	I-GENE
myc	I-GENE
alleles	O
into	O
murine	O
cells	O
and	O
Xenopus	O
oocyte	O
germinal	O
vesicles	O
.	O


From	O
an	O
RNK	O
-	O
16	O
lambda	O
-	O
gt11	O
library	O
,	O
we	O
have	O
isolated	O
and	O
sequenced	O
a	O
novel	O
cDNA	O
rat	B-GENE
NK	I-GENE
cell	I-GENE
protease	I-GENE
1	I-GENE
(	O
RNKP	B-GENE
-	I-GENE
1	I-GENE
)	O
that	O
has	O
characteristics	O
unique	O
to	O
serine	B-GENE
proteases	I-GENE
.	O


Patients	O
with	O
acute	O
myocardial	O
infarction	O
had	O
higher	O
plasma	O
concentrations	O
of	O
neutrophil	B-GENE
elastase	I-GENE
and	O
the	O
non	O
-	O
peroxide	O
diene	O
conjugated	O
isomer	O
of	O
linoleic	O
acid	O
than	O
normal	O
volunteers	O
or	O
patients	O
with	O
stable	O
ischaemic	O
heart	O
disease	O
.	O


TMBr	B-GENE
-	I-GENE
1	I-GENE
is	O
identical	O
to	O
striated	B-GENE
muscle	I-GENE
alpha	I-GENE
-	I-GENE
tropomyosin	I-GENE
from	O
amino	O
acids	O
1	O
through	O
258	O
but	O
contains	O
a	O
novel	O
COOH	O
-	O
terminal	O
region	O
from	O
amino	O
acids	O
259	O
through	O
281	O
.	O


Comparison	O
of	O
transmembrane	O
and	O
cytoplasmic	O
domains	O
to	O
a	O
third	O
cell	O
-	O
surface	O
proteoglycan	O
,	O
48K5	B-GENE
from	O
human	O
lung	O
fibroblasts	O
(	O
Marynen	O
,	O
P	O
.	O
,	O
Zhang	O
,	O
J	O
.	O
,	O
Cassiman	O
,	O
J	O
.	O
,	O
Vanden	O
Berghe	O
,	O
H	O
.	O
,	O
and	O
David	O
,	O
C	O
.	O


High	O
levels	O
of	O
C	B-GENE
subunits	I-GENE
are	O
observed	O
in	O
several	O
subsequent	O
larval	O
and	O
adult	O
stages	O
of	O
development	O
.	O


Plasma	O
lecithin	B-GENE
/	I-GENE
cholesterol	I-GENE
acyltransferase	I-GENE
(	O
LCAT	B-GENE
)	O
activity	O
in	O
multiple	O
-	O
organ	O
donors	O
:	O
a	O
predictor	O
of	O
allograft	O
viability	O
in	O
clinical	O
liver	O
transplantation	O
.	O


Expression	O
,	O
cellular	O
localization	O
and	O
in	O
vitro	O
transcription	O
studies	O
establish	O
that	O
cloned	B-GENE
hUBF	I-GENE
encodes	O
a	O
nucleolar	O
factor	O
that	O
binds	O
specifically	O
to	O
the	O
upstream	O
control	O
element	O
and	O
core	O
of	O
the	O
rRNA	O
gene	O
promoter	O
to	O
activate	O
transcription	O
in	O
a	O
binding	O
site	O
-	O
dependent	O
manner	O
.	O


The	O
distribution	O
of	O
their	O
fibrinogen	B-GENE
levels	O
was	O
Gaussian	O
,	O
but	O
more	O
wide	O
-	O
based	O
than	O
the	O
distribution	O
of	O
our	O
normal	O
controls	O
.	O


An	O
NF1	B-GENE
-	I-GENE
related	I-GENE
vitellogenin	I-GENE
activator	I-GENE
element	I-GENE
mediates	O
transcription	O
from	O
the	O
estrogen	O
-	O
regulated	O
Xenopus	B-GENE
laevis	I-GENE
vitellogenin	I-GENE
promoter	I-GENE
.	O


These	O
findings	O
indicate	O
that	O
hypergastrinemia	O
induced	O
by	O
surgical	O
removal	O
of	O
acid	O
-	O
producing	O
mucosa	O
in	O
the	O
rat	O
has	O
the	O
same	O
effects	O
on	O
oxyntical	O
mucosal	B-GENE
HDC	I-GENE
activity	O
,	O
histamine	O
concentration	O
and	O
ECL	O
cell	O
density	O
as	O
hypergastrinemia	O
induced	O
by	O
continuous	O
gastrin	B-GENE
infusion	O
or	O
by	O
long	O
-	O
term	O
treatment	O
with	O
effective	O
antisecretagogues	O
.	O


A	O
consensus	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
SP1	B-GENE
was	O
identified	O
in	O
intron	O
As	O
downstream	O
of	O
the	O
proenkephalin	B-GENE
germ	I-GENE
cell	I-GENE
cap	I-GENE
site	I-GENE
region	I-GENE
.	O


PCR	O
-	O
derived	O
fragments	O
were	O
used	O
as	O
probes	O
for	O
the	O
isolation	O
of	O
the	O
U3	B-GENE
snRNA	I-GENE
genes	I-GENE
from	O
a	O
genomic	O
library	O
of	O
Arabidopsis	O
.	O


However	O
,	O
at	O
18	O
months	O
of	O
age	O
,	O
significantly	O
higher	O
levels	O
of	O
IgG1	B-GENE
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
of	O
IgG4	B-GENE
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
were	O
found	O
in	O
infants	O
with	O
an	O
elevated	O
IgE	B-GENE
(	O
greater	O
than	O
or	O
equal	O
to	O
8	O
.	O
0	O
kU	O
/	O
l	O
)	O
than	O
in	O
those	O
with	O
a	O
lower	O
level	O
.	O


The	O
results	O
also	O
showed	O
that	O
although	O
oyster	O
shell	O
supplementation	O
generally	O
increased	O
alkaline	B-GENE
phosphatase	I-GENE
activity	O
,	O
bone	O
mineralization	O
was	O
relatively	O
uninfluenced	O
as	O
judged	O
by	O
the	O
low	O
coefficients	O
of	O
variation	O
(	O
CV	O
)	O
of	O
3	O
.	O
14	O
-	O
3	O
.	O
51	O
%	O
and	O
3	O
.	O
39	O
-	O
4	O
.	O
82	O
%	O
for	O
calcium	O
and	O
phosphorus	O
content	O
in	O
the	O
femur	O
and	O
tibia	O
respectively	O
.	O


Serotonin	B-GENE
5	I-GENE
-	I-GENE
HT2	I-GENE
receptor	I-GENE
binding	O
on	O
blood	O
platelets	O
as	O
a	O
state	O
dependent	O
marker	O
in	O
major	O
affective	O
disorder	O
.	O


Eucaryotic	O
transcription	O
factors	O
that	O
stimulate	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
by	O
increasing	O
the	O
efficiency	O
of	O
elongation	O
of	O
specifically	O
or	O
randomly	O
initiated	O
RNA	O
chains	O
have	O
been	O
isolated	O
and	O
characterized	O
.	O


The	O
trk	B-GENE
-	I-GENE
2h	I-GENE
oncogene	I-GENE
,	O
isolated	O
from	O
the	O
human	O
breast	O
carcinoma	O
cell	O
line	O
MDA	O
-	O
MB	O
231	O
by	O
genomic	O
DNA	O
-	O
transfection	O
into	O
NIH3T3	O
cells	O
,	O
consists	O
of	O
the	O
trk	B-GENE
proto	I-GENE
-	I-GENE
oncogene	I-GENE
receptor	I-GENE
kinase	I-GENE
domain	I-GENE
fused	O
to	O
a	O
N	O
-	O
terminal	O
41	O
amino	O
acid	O
activating	O
sequence	O
(	O
Kozma	O
,	O
S	O
.	O
C	O
.	O
,	O
Redmond	O
,	O
S	O
.	O
M	O
.	O
S	O
.	O
,	O
Xiao	O
-	O
Chang	O
,	O
F	O
.	O
,	O
Saurer	O
,	O
S	O
.	O
M	O
.	O
,	O
Groner	O
,	O
B	O
.	O
and	O
Hynes	O
,	O
N	O
.	O
E	O
.	O


Antibodies	O
raised	O
against	O
a	O
bacterially	O
produced	O
beta	B-GENE
gal	I-GENE
-	O
trk	B-GENE
receptor	O
kinase	O
fusion	O
protein	O
recognized	O
a	O
44	O
kd	O
phosphoprotein	O
phosphorylated	O
on	O
serine	O
,	O
threonine	O
and	O
tyrosine	O
in	O
extracts	O
of	O
trk	B-GENE
-	I-GENE
2h	I-GENE
transformed	O
NIH3T3	O
cells	O
.	O


Molecular	O
and	O
functional	O
characterization	O
of	O
the	O
promoter	O
of	O
ETS2	B-GENE
,	O
the	O
human	O
c	B-GENE
-	I-GENE
ets	I-GENE
-	I-GENE
2	I-GENE
gene	O
.	O


An	O
examination	O
of	O
the	O
properties	O
of	O
sequences	O
surrounding	O
ARS1	O
left	O
open	O
the	O
possibility	O
that	O
ABFI	B-GENE
enhances	O
the	O
initiation	O
of	O
DNA	O
replication	O
at	O
ARS1	O
by	O
transcriptional	O
activation	O
.	O


The	O
priming	O
activity	O
of	O
DNA	O
incised	O
by	O
either	O
of	O
the	O
Drosophila	O
enzymes	O
can	O
be	O
enhanced	O
,	O
however	O
,	O
by	O
an	O
additional	O
incubation	O
with	O
E	B-GENE
.	I-GENE
coli	I-GENE
endonuclease	I-GENE
IV	I-GENE
,	O
which	O
is	O
known	O
to	O
cleave	O
depurinated	O
DNA	O
on	O
the	O
5	O
'	O
-	O
side	O
of	O
an	O
apurinic	O
site	O
.	O


The	O
levels	O
of	O
both	O
MAP1	B-GENE
-	I-GENE
specific	I-GENE
and	I-GENE
MAP2	I-GENE
-	I-GENE
specific	I-GENE
mRNAs	I-GENE
decline	O
in	O
the	O
postnatal	O
developing	O
brain	O
;	O
the	O
level	O
of	O
MAP1	B-GENE
-	I-GENE
specific	I-GENE
mRNA	I-GENE
also	O
increases	O
slightly	O
in	O
rat	O
PC12	O
cells	O
upon	O
exposure	O
to	O
nerve	B-GENE
growth	I-GENE
factor	I-GENE
.	O


Deletion	O
analysis	O
was	O
carried	O
out	O
within	O
a	O
part	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
showing	O
homology	O
to	O
the	O
upstream	O
region	O
of	O
the	O
yeast	B-GENE
CYC1	I-GENE
gene	I-GENE
.	O


Lysozyme	B-GENE
activity	O
was	O
evidently	O
increased	O
as	O
well	O
in	O
undiluted	O
as	O
in	O
diluted	O
sera	O
in	O
all	O
our	O
tested	O
patients	O
.	O


A	O
5	B-GENE
.	I-GENE
8S	I-GENE
-	I-GENE
like	I-GENE
structure	I-GENE
is	O
present	O
within	O
the	O
5	O
'	O
-	O
terminal	O
region	O
of	O
all	O
three	O
fungal	B-GENE
mitochondrial	I-GENE
LSU	I-GENE
rRNAs	I-GENE
;	O
in	O
contrast	O
,	O
no	O
4	B-GENE
.	I-GENE
5S	I-GENE
-	I-GENE
like	I-GENE
structure	I-GENE
is	O
evident	O
at	O
the	O
3	O
'	O
end	O
of	O
these	O
molecules	O
.	O


ASL	O
-	O
8123	O
demonstrated	O
weak	O
competitive	O
beta	B-GENE
-	I-GENE
adrenoreceptor	I-GENE
blocking	O
activity	O
in	O
isolated	O
guinea	O
pig	O
right	O
atria	O
with	O
a	O
pA2	O
of	O
3	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
07	O
;	O
no	O
agonist	O
-	O
like	O
activity	O
was	O
observed	O
in	O
this	O
tissue	O
at	O
concentrations	O
of	O
ASL	O
-	O
8123	O
from	O
3	O
X	O
10	O
(	O
-	O
5	O
)	O
to	O
1	O
X	O
10	O
(	O
-	O
2	O
)	O
M	O
.	O


The	O
size	O
discrepancy	O
is	O
not	O
due	O
to	O
glycosylation	O
or	O
phosphorylation	O
of	O
Ag35	B-GENE
but	O
may	O
result	O
from	O
a	O
proline	O
-	O
rich	O
sequence	O
which	O
occurs	O
in	O
this	O
polypeptide	O
.	O


Serum	O
prostatic	B-GENE
acid	I-GENE
phosphatase	I-GENE
levels	O
showed	O
a	O
significantly	O
weaker	O
correlation	O
with	O
cancer	O
volume	O
(	O
r	O
equals	O
0	O
.	O
51	O
)	O
and	O
every	O
other	O
pathological	O
parameter	O
.	O


The	O
investigation	O
was	O
thereafter	O
continued	O
in	O
an	O
open	O
fashion	O
by	O
administering	O
a	O
single	O
10	O
mg	O
dose	O
of	O
the	O
MAO	B-GENE
-	I-GENE
B	I-GENE
inhibitor	O
deprenyl	O
to	O
the	O
same	O
subjects	O
.	O


This	O
approach	O
was	O
examined	O
utilizing	O
the	O
fetal	O
protein	O
,	O
HGB	B-GENE
F	I-GENE
.	O


In	O
addition	O
to	O
the	O
significant	O
reduction	O
in	O
blood	O
pressure	O
,	O
the	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
(	O
ACE	B-GENE
)	O
inhibitor	O
ramipril	O
caused	O
a	O
significant	O
regression	O
of	O
pathologic	O
left	O
ventricular	O
hypertrophy	O
demonstrated	O
by	O
magnetic	O
resonance	O
imaging	O
and	O
echocardiography	O
.	O


Previously	O
,	O
we	O
reported	O
the	O
sequence	O
of	O
the	O
gene	B-GENE
encoding	I-GENE
human	I-GENE
K14	I-GENE
(	O
D	O
.	O


Similarly	O
,	O
a	O
human	O
but	O
not	O
a	O
bovine	B-GENE
alpha	I-GENE
transgene	I-GENE
was	O
expressed	O
in	O
placenta	O
in	O
transgenic	O
mice	O
.	O


The	O
diagnostic	O
value	O
of	O
blood	O
serum	O
and	O
urinary	B-GENE
amylase	I-GENE
,	O
lipase	B-GENE
,	O
and	O
trypsin	B-GENE
in	O
exacerbations	O
of	O
chronic	O
relapsing	O
pancreatitis	O
is	O
discussed	O
.	O


Intravenous	O
gamma	B-GENE
globulins	I-GENE


Once	O
NGF	B-GENE
administration	O
is	O
proven	O
effective	O
it	O
will	O
be	O
possible	O
to	O
develop	O
alternative	O
ways	O
of	O
NGF	B-GENE
administration	O
.	O


The	O
thrombolytic	O
effects	O
of	O
native	O
tissue	B-GENE
-	I-GENE
type	I-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
AK	B-GENE
-	I-GENE
124	I-GENE
)	O
on	O
experimental	O
canine	O
coronary	O
thrombosis	O
.	O


However	O
,	O
experiments	O
with	O
S1	B-GENE
mapping	O
of	O
in	O
vivo	O
transcripts	O
,	O
gene	O
disruptions	O
in	O
the	O
alpha	O
region	O
,	O
and	O
a	O
single	O
-	O
copy	O
transcriptional	O
fusion	O
vector	O
all	O
suggested	O
that	O
these	O
possible	O
promoters	O
were	O
largely	O
inactive	O
during	O
logarithmic	O
growth	O
,	O
that	O
the	O
major	O
promoter	O
for	O
the	O
alpha	O
operon	O
lay	O
upstream	O
from	O
the	O
region	O
cloned	O
,	O
and	O
that	O
the	O
genes	O
in	O
the	O
IF1	B-GENE
to	O
L17	B-GENE
interval	O
were	O
cotranscribed	O
.	O


Tonometry	O
of	O
blood	O
samples	O
from	O
patients	O
may	O
also	O
be	O
used	O
in	O
the	O
determination	O
of	O
acid	O
-	O
base	O
quantities	O
and	O
hemoglobin	B-GENE
-	O
oxygen	O
affinity	O
e	O
.	O
g	O
.	O
p50	O
.	O


Among	O
100	O
cases	O
of	O
post	O
-	O
transfusion	O
hepatitis	O
,	O
10	O
are	O
due	O
to	O
the	O
hepatitis	O
B	O
virus	O
(	O
despite	O
systematic	O
search	O
for	O
HBs	B-GENE
Ag	I-GENE
)	O
,	O
89	O
are	O
due	O
to	O
one	O
of	O
the	O
non	O
-	O
A	O
non	O
-	O
B	O
viruses	O
(	O
not	O
detectable	O
by	O
specific	O
serological	O
tests	O
)	O
and	O
1	O
to	O
several	O
viruses	O
,	O
specially	O
CMV	O
.	O


A	O
215	O
-	O
base	O
-	O
pair	O
(	O
bp	O
)	O
region	O
of	O
the	O
mouse	B-GENE
MOPC	I-GENE
41	I-GENE
kappa	I-GENE
light	I-GENE
-	I-GENE
chain	I-GENE
immunoglobulin	I-GENE
gene	I-GENE
enhancer	I-GENE
has	O
been	O
analyzed	O
for	O
specific	O
binding	O
of	O
lymphoid	O
and	O
nonlymphoid	O
nuclear	O
factors	O
.	O


Mapping	O
of	O
RNA	O
-	O
temperature	B-GENE
-	I-GENE
sensitive	I-GENE
mutants	I-GENE
of	I-GENE
Sindbis	I-GENE
virus	I-GENE
:	I-GENE
complementation	I-GENE
group	I-GENE
F	I-GENE
mutants	I-GENE
have	O
lesions	O
in	O
nsP4	B-GENE
.	O


S1	B-GENE
nuclease	I-GENE
analysis	O
of	O
RNA	O
prepared	O
after	O
transfection	O
of	O
these	O
HIV	O
constructs	O
into	O
HeLa	O
cells	O
infected	O
with	O
wild	O
-	O
type	O
adenovirus	O
indicated	O
that	O
the	O
enhancer	O
,	O
SP1	B-GENE
,	O
TATA	O
,	O
and	O
a	O
portion	O
of	O
the	O
transactivation	O
-	O
responsive	O
element	O
were	O
each	O
required	O
for	O
complete	O
E1A	B-GENE
/	O
E1B	B-GENE
-	O
mediated	O
activation	O
of	O
the	O
HIV	B-GENE
LTR	I-GENE
.	O


In	O
supine	O
position	O
,	O
plasma	O
ANP	B-GENE
levels	O
ranged	O
from	O
12	O
pg	O
/	O
ml	O
to	O
51	O
.	O
5	O
pg	O
/	O
ml	O
,	O
with	O
an	O
average	O
level	O
of	O
35	O
.	O
3	O
+	O
/	O
-	O
11	O
.	O
5	O
pg	O
/	O
ml	O
.	O


In	O
HeLa	O
cells	O
,	O
it	O
activated	O
transcription	O
from	O
the	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
thymidine	I-GENE
kinase	I-GENE
promoter	I-GENE
linked	O
to	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
gene	I-GENE
when	O
located	O
in	O
inverted	O
orientation	O
upstream	O
of	O
the	O
thymidine	B-GENE
kinase	I-GENE
promoter	I-GENE
or	O
downstream	O
of	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
gene	I-GENE
coding	I-GENE
sequence	I-GENE
.	O


At	O
the	O
basal	O
unstimulated	O
condition	O
,	O
Ren1d	B-GENE
5	I-GENE
'	I-GENE
flanking	I-GENE
sequence	I-GENE
in	O
the	O
sense	O
orientation	O
inhibited	O
basal	O
CAT	B-GENE
expression	O
from	O
the	O
TK	B-GENE
promoter	I-GENE
of	O
pUTKAT1	O
,	O
whereas	O
the	O
same	O
sequence	O
in	O
the	O
antisense	O
orientation	O
did	O
not	O
.	O


We	O
have	O
isolated	O
cDNA	O
clones	O
from	O
rat	O
brain	O
and	O
human	O
liver	O
encoding	O
a	O
putative	O
isoform	O
of	O
the	O
Na	B-GENE
,	I-GENE
K	I-GENE
-	I-GENE
ATPase	I-GENE
beta	I-GENE
subunit	I-GENE
.	O


UbiA	B-GENE
is	O
also	O
unique	O
among	O
known	O
polyubiquitin	B-GENE
genes	I-GENE
in	O
containing	O
four	O
cis	O
-	O
spliced	O
introns	O
within	O
its	O
coding	O
sequence	O
.	O


The	O
methylation	O
of	O
nuclear	O
and	O
chloroplast	O
DNAs	O
has	O
been	O
examined	O
in	O
relation	O
to	O
the	O
known	O
differential	O
expression	O
of	O
C4	B-GENE
photosynthesis	I-GENE
genes	I-GENE
in	O
the	O
bundle	O
sheath	O
and	O
mesophyll	O
cells	O
of	O
etiolated	O
,	O
greening	O
,	O
and	O
fully	O
green	O
maize	O
leaves	O
.	O


Synthetic	O
oligonucleotides	O
representing	O
the	O
19	O
bp	O
repeat	O
unit	O
strongly	O
reduced	O
the	O
activity	O
of	O
the	O
IE1	B-GENE
/	I-GENE
2	I-GENE
enhancer	I-GENE
/	I-GENE
promoter	I-GENE
in	O
cotransfection	O
assays	O
after	O
transient	O
expression	O
.	O


The	O
mustard	B-GENE
chloroplast	I-GENE
gene	I-GENE
rps16	I-GENE
is	O
split	O
by	O
an	O
887	O
bp	O
group	O
II	O
(	O
or	O
III	O
)	O
intron	O
.	O


The	O
unique	O
nature	O
and	O
arrangement	O
of	O
the	O
ANT1	B-GENE
transcriptional	I-GENE
control	I-GENE
elements	I-GENE
may	O
account	O
for	O
this	O
differential	O
expression	O
.	O


VP5	B-GENE
,	O
which	O
encodes	O
the	O
major	B-GENE
capsid	I-GENE
protein	I-GENE
,	O
each	O
fused	O
to	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
gene	I-GENE
.	O


Insert2	O
contains	O
repetitive	O
non	O
-	O
Ig	B-GENE
-	O
related	O
sequences	O
and	O
a	O
small	B-GENE
Ig	I-GENE
-	I-GENE
related	I-GENE
sequence	I-GENE
.	O


Since	O
considerable	O
variations	O
in	O
length	O
and	O
primary	O
sequence	O
in	O
the	O
CDR3	B-GENE
(	O
complementarity	B-GENE
determining	I-GENE
region	I-GENE
)	O
peptides	O
of	O
all	O
the	O
H	B-GENE
-	I-GENE
chains	I-GENE
are	O
evident	O
,	O
conservation	O
of	O
the	O
D	B-GENE
-	I-GENE
region	I-GENE
structure	O
does	O
not	O
appear	O
to	O
be	O
necessary	O
for	O
effective	O
hapten	O
binding	O
.	O


The	O
DNA	O
helix	O
at	O
the	O
tandemly	O
repeated	O
,	O
13mer	O
sequence	O
is	O
thermodynamically	O
unstable	O
,	O
as	O
evidenced	O
by	O
hypersensitivity	O
to	O
single	B-GENE
-	I-GENE
strand	I-GENE
-	I-GENE
specific	I-GENE
nuclease	I-GENE
in	O
a	O
negatively	O
supercoiled	O
plasmid	O
,	O
and	O
demonstrated	O
by	O
stable	O
DNA	O
unwinding	O
seen	O
after	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
of	O
topoisomers	O
.	O


Other	O
hemostatic	O
values	O
evaluated	O
were	O
activated	O
partial	O
thromboplastin	B-GENE
times	O
,	O
prothrombin	B-GENE
times	O
,	O
thrombin	B-GENE
times	O
,	O
fibrinogen	B-GENE
,	O
platelet	O
counts	O
,	O
and	O
fibrin	B-GENE
/	O
fibrinogen	B-GENE
degradation	O
products	O
.	O


We	O
have	O
designated	O
the	O
protein	O
"	B-GENE
cellular	I-GENE
NBP	I-GENE
"	I-GENE
(	O
CNBP	B-GENE
)	O
.	O


Isolation	O
and	O
characterization	O
of	O
a	O
cDNA	O
encoding	O
a	O
putative	O
cytokine	O
which	O
is	O
induced	O
by	O
stimulation	O
via	O
the	O
CD2	B-GENE
structure	I-GENE
on	O
human	O
T	O
lymphocytes	O
.	O


Tumour	B-GENE
necrosis	I-GENE
factor	I-GENE
and	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O


To	O
assess	O
the	O
functional	O
importance	O
of	O
these	O
NBS	O
in	O
the	O
overall	O
drug	O
resistance	O
phenotype	O
conferred	O
by	O
mdr1	B-GENE
,	O
we	O
introduced	O
amino	O
acid	O
substitutions	O
in	O
the	O
core	O
consensus	O
sequence	O
for	O
nucleotide	O
binding	O
,	O
GXGKST	O
.	O


Northern	O
blot	O
analysis	O
revealed	O
multiple	O
oIGF	B-GENE
-	I-GENE
I	I-GENE
transcripts	I-GENE
in	O
a	O
broad	O
band	O
at	O
800	O
-	O
1	O
,	O
100	O
nucleotides	O
and	O
other	O
transcripts	O
of	O
higher	O
molecular	O
weight	O
in	O
liver	O
.	O


After	O
hepatitis	O
B	O
vaccine	O
immunization	O
,	O
serum	O
antibody	O
response	O
was	O
of	O
primary	O
type	O
in	O
33	O
cases	O
with	O
anti	B-GENE
-	I-GENE
HBs	I-GENE
less	O
than	O
2	O
.	O
1	O
S	O
/	O
N	O
(	O
S	O
/	O
N	O
Ratio	O
Unit	O
)	O
at	O
T0	O
,	O
the	O
anti	B-GENE
-	I-GENE
HBs	I-GENE
positive	O
rate	O
was	O
39	O
.	O
4	O
%	O
,	O
84	O
.	O
8	O
%	O
,	O
96	O
.	O
7	O
%	O
and	O
96	O
.	O
7	O
%	O
in	O
T1	O
,	O
T2	O
,	O
T0	O
and	O
T12	O
respectively	O
.	O


Analysis	O
of	O
the	O
inferred	O
1	B-GENE
,	I-GENE
859	I-GENE
-	I-GENE
residue	I-GENE
ama	I-GENE
-	I-GENE
1	I-GENE
product	I-GENE
showed	O
considerable	O
identity	O
with	O
the	O
largest	O
subunit	O
of	O
RNAP	B-GENE
II	I-GENE
from	O
other	O
organisms	O
,	O
including	O
the	O
presence	O
of	O
a	O
zinc	O
finger	O
motif	O
near	O
the	O
amino	O
terminus	O
,	O
and	O
a	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
42	O
tandemly	O
reiterated	O
heptamers	O
with	O
the	O
consensus	O
Tyr	O
Ser	O
Pro	O
Thr	O
Ser	O
Pro	O
Ser	O
.	O


Of	O
165	O
women	O
with	O
non	O
-	O
malignant	O
diagnoses	O
26	O
(	O
16	O
%	O
)	O
had	O
CA	B-GENE
125	I-GENE
levels	O
in	O
excess	O
of	O
35	O
U	O
/	O
ml	O
and	O
8	O
(	O
5	O
%	O
)	O
greater	O
than	O
65	O
U	O
/	O
ml	O
.	O


The	O
elements	O
responsible	O
for	O
glucocorticoid	O
stimulation	O
of	O
ADH	B-GENE
gene	I-GENE
transcription	O
appear	O
to	O
reside	O
outside	O
of	O
this	O
region	O
.	O


The	O
two	O
most	O
recent	O
patients	O
(	O
35	O
and	O
132	O
days	O
)	O
received	O
only	O
oral	O
dipyridamole	O
(	O
75	O
mg	O
X	O
3	O
/	O
day	O
)	O
and	O
aspirin	O
(	O
80	O
mg	O
/	O
day	O
)	O
after	O
the	O
early	O
recovery	O
period	O
(	O
four	O
-	O
six	O
days	O
)	O
,	O
resulting	O
in	O
normal	O
prothrombin	B-GENE
and	O
partial	O
thromboplastin	B-GENE
times	O
.	O


Gel	O
retardation	O
assays	O
combined	O
with	O
DNase	B-GENE
I	I-GENE
footprinting	O
and	O
diethyl	O
pyrocarbonate	O
interference	O
showed	O
that	O
a	O
nuclear	O
factor	O
from	O
differentiated	O
C2	O
myotubes	O
and	O
BC3H1	O
myocytes	O
recognized	O
a	O
conserved	O
A	O
+	O
T	O
-	O
rich	O
sequence	O
within	O
the	O
peripheral	O
activating	O
region	O
.	O


During	O
challenge	O
,	O
rebiopsy	O
was	O
done	O
when	O
reticulin	B-GENE
antibodies	I-GENE
turned	O
positive	O
(	O
mean	O
0	O
.	O
6	O
years	O
,	O
range	O
0	O
.	O
2	O
-	O
2	O
.	O
0	O
)	O
or	O
at	O
the	O
end	O
of	O
the	O
two	O
year	O
study	O
.	O


Serological	O
studies	O
at	O
the	O
early	O
relapse	O
stage	O
of	O
this	O
disease	O
showed	O
increased	O
serum	B-GENE
ANA	I-GENE
,	O
IgA	B-GENE
and	O
IgM	B-GENE
level	O
with	O
normal	O
IgG	B-GENE
and	O
decrease	O
of	O
C3	B-GENE
and	O
C4	B-GENE
.	O


Concomitant	O
chronic	O
lymphocytic	O
leukemia	O
,	O
acute	O
myeloid	O
leukemia	O
,	O
and	O
thrombosis	O
with	O
protein	B-GENE
C	I-GENE
deficiency	O
.	O


In	O
the	O
whole	O
group	O
,	O
basal	O
GH	B-GENE
and	O
somatomedin	B-GENE
-	I-GENE
C	I-GENE
levels	O
decreased	O
from	O
a	O
mean	O
(	O
+	O
/	O
-	O
standard	O
error	O
of	O
the	O
mean	O
)	O
of	O
52	O
.	O
3	O
+	O
/	O
-	O
12	O
.	O
7	O
to	O
11	O
.	O
1	O
+	O
/	O
-	O
6	O
.	O
3	O
ng	O
/	O
ml	O
and	O
from	O
7	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
U	O
/	O
ml	O
,	O
respectively	O
.	O


Furthermore	O
,	O
formation	O
of	O
foci	O
of	O
transformed	O
RECs	O
by	O
the	O
c	B-GENE
-	I-GENE
jun	I-GENE
/	O
ras	B-GENE
combination	O
was	O
augmented	O
3	O
-	O
fold	O
by	O
the	O
tumor	O
promoter	O
phorbol	O
12	O
-	O
tetradecanoate	O
13	O
-	O
acetate	O
.	O


There	O
was	O
no	O
significant	O
correlation	O
between	O
baseline	O
PC40	O
methacholine	O
and	O
the	O
maximal	O
fall	O
in	O
Vp30	O
after	O
either	O
the	O
first	O
(	O
12	O
micrograms	O
)	O
or	O
the	O
second	O
dose	O
(	O
24	O
micrograms	O
)	O
of	O
platelet	B-GENE
activating	I-GENE
factor	I-GENE
.	O


Although	O
it	O
is	O
well	O
known	O
that	O
calcium	O
channel	O
blockers	O
can	O
influence	O
contraction	O
of	O
vascular	O
smooth	O
muscle	O
,	O
there	O
is	O
less	O
knowledge	O
on	O
its	O
effect	O
on	O
excitation	O
contraction	O
coupling	O
in	O
the	O
endocrine	O
glands	O
and	O
more	O
specifically	O
on	O
insulin	B-GENE
and	O
glucagon	B-GENE
release	O
.	O


The	O
site	O
-	O
specific	O
DNA	O
inversion	O
system	O
Cin	B-GENE
encoded	O
by	O
the	O
bacteriophage	O
P1	O
consists	O
of	O
a	O
recombinase	B-GENE
,	O
two	O
inverted	O
crossing	O
-	O
over	O
sites	O
and	O
a	O
recombinational	O
enhancer	O
.	O


Tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(	O
TNF	B-GENE
)	O
is	O
reported	O
to	O
cause	O
a	O
shock	O
syndrome	O
similar	O
to	O
that	O
produced	O
by	O
endotoxin	O
(	O
LPS	O
)	O
.	O


Of	O
the	O
single	O
-	O
stranded	O
DNA	O
transformants	O
,	O
65	O
%	O
resulted	O
from	O
replacement	O
of	O
the	O
resident	O
met2	B-GENE
mutation	I-GENE
by	O
the	O
exogenous	O
wild	O
-	O
type	O
allele	O
.	O


The	O
results	O
strongly	O
support	O
the	O
notion	O
that	O
the	O
OBF1	B-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
and	O
the	O
OBF1	B-GENE
protein	I-GENE
are	O
important	O
for	O
normal	O
ARS	O
function	O
as	O
an	O
origin	O
of	O
replication	O
.	O


Four	O
out	O
of	O
10	O
patients	O
showed	O
clinical	O
improvement	O
according	O
to	O
Ritchie	O
-	O
Index	O
,	O
pain	O
score	O
,	O
ESR	O
and	O
CRP	B-GENE
.	O


The	O
R	B-GENE
.	I-GENE
meliloti	I-GENE
nifH	I-GENE
promoter	I-GENE
but	O
not	O
the	O
K	B-GENE
.	I-GENE
pneumoniae	I-GENE
nifH	I-GENE
promoter	I-GENE
showed	O
sigma	B-GENE
54	I-GENE
-	O
dependent	O
methylation	O
protection	O
of	O
guanine	O
residues	O
at	O
-	O
14	O
,	O
-	O
25	O
and	O
-	O
26	O
,	O
the	O
most	O
conserved	O
nucleotides	O
characteristic	O
of	O
sigma	B-GENE
54	I-GENE
-	I-GENE
dependent	I-GENE
promoters	I-GENE
.	O


To	O
assess	O
the	O
health	O
significance	O
of	O
the	O
early	O
renal	O
changes	O
after	O
chronic	O
exposure	O
to	O
cadmium	O
,	O
23	O
workers	O
removed	O
from	O
exposure	O
because	O
of	O
the	O
discovery	O
of	O
an	O
increased	O
urinary	O
excretion	O
of	O
beta	B-GENE
2	I-GENE
-	I-GENE
microglobulin	I-GENE
or	O
retinol	B-GENE
binding	I-GENE
protein	I-GENE
,	O
or	O
both	O
,	O
have	O
been	O
examined	O
once	O
a	O
year	O
for	O
five	O
years	O
.	O


The	O
cytosolic	O
glutathione	B-GENE
S	I-GENE
-	I-GENE
transferases	I-GENE
(	O
GSTs	B-GENE
,	O
EC	B-GENE
2	I-GENE
.	I-GENE
5	I-GENE
.	I-GENE
1	I-GENE
.	I-GENE
18	I-GENE
)	O
are	O
a	O
superfamily	O
of	O
dimeric	O
isoenzymes	O
which	O
catalyze	O
the	O
conjugation	O
of	O
electrophilic	O
substrates	O
with	O
glutathione	O
.	O


The	O
present	O
data	O
also	O
suggest	O
that	O
when	O
compared	O
to	O
the	O
systemic	O
vascular	O
bed	O
,	O
the	O
pulmonary	O
vascular	O
bed	O
is	O
less	O
responsive	O
to	O
bolus	O
administration	O
of	O
ET	B-GENE
-	I-GENE
1	I-GENE
.	O


Diagnosis	O
of	O
primary	O
sclerosing	O
cholangitis	O
in	O
a	O
blood	O
donor	O
with	O
elevated	O
serum	B-GENE
alanine	I-GENE
aminotransferase	I-GENE
.	O


Primer	O
extension	O
experiments	O
indicated	O
that	O
the	O
transcription	O
initiation	O
site	O
mapped	O
to	O
a	O
position	O
on	O
gene	B-GENE
IV	I-GENE
that	O
was	O
analogous	O
to	O
that	O
reported	O
for	O
the	O
structurally	O
similar	O
P	B-GENE
-	I-GENE
450e	I-GENE
gene	I-GENE
.	O


From	O
day	O
30	O
after	O
turnout	O
,	O
the	O
PFB	O
-	O
group	O
had	O
significantly	O
lower	O
serum	B-GENE
pepsinogen	I-GENE
levels	O
,	O
which	O
reflects	O
the	O
low	O
degree	O
of	O
abomasal	O
damage	O
in	O
these	O
animals	O
.	O


Chronic	O
dose	O
effects	O
of	O
methyl	O
parathion	O
on	O
nuthatches	O
:	O
cholinesterase	B-GENE
and	O
ptilochronology	O
.	O


Similarly	O
,	O
the	O
sequence	O
of	O
the	O
U2	B-GENE
RNA	I-GENE
region	I-GENE
shown	O
to	O
be	O
involved	O
in	O
pre	O
-	O
mRNA	O
branchpoint	O
recognition	O
in	O
yeast	O
,	O
and	O
exactly	O
conserved	O
in	O
metazoan	B-GENE
U2	I-GENE
RNAs	I-GENE
,	O
was	O
totally	O
divergent	O
in	O
trypanosomes	O
.	O


It	O
is	O
striking	O
that	O
the	O
active	O
CHO	O
spacer	O
promoter	O
violated	O
the	O
otherwise	O
universal	O
rule	O
that	O
metazoan	B-GENE
RNA	I-GENE
polymerase	I-GENE
I	I-GENE
promoters	I-GENE
all	O
have	O
a	O
G	O
residue	O
at	O
position	O
-	O
16	O
.	O


In	O
the	O
final	O
model	O
,	O
grade	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
,	O
peritoneal	O
cytologic	O
results	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
,	O
progesterone	B-GENE
receptor	I-GENE
status	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
,	O
and	O
age	O
as	O
a	O
continuous	O
variable	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
were	O
most	O
closely	O
associated	O
with	O
disease	O
-	O
free	O
survival	O
.	O


Transcripts	O
characterized	O
include	O
(	O
i	O
)	O
abundant	O
monocistronic	O
L11e	B-GENE
and	O
tricistronic	O
L1e	B-GENE
-	O
L10e	B-GENE
-	O
L12e	B-GENE
transcripts	O
;	O
(	O
ii	O
)	O
less	O
abundant	O
bicistronic	O
NAB	B-GENE
-	O
L11e	B-GENE
and	O
monocistronic	O
NAB	B-GENE
transcripts	I-GENE
and	O
(	O
iii	O
)	O
a	O
very	O
rare	O
ORF	O
monocistronic	O
transcript	O
.	O


This	O
suggested	O
that	O
baboon	B-GENE
liver	I-GENE
class	I-GENE
I	I-GENE
ADH	I-GENE
is	O
of	O
the	O
same	O
ancestral	O
lineage	O
as	O
the	O
human	B-GENE
ADH	I-GENE
-	I-GENE
beta	I-GENE
.	O


Brain	B-GENE
cholinesterase	I-GENE
activity	O
of	O
nestling	O
great	O
egrets	O
,	O
snowy	O
egrets	O
and	O
black	O
-	O
crowned	O
night	O
-	O
herons	O
.	O
inhibition	O
of	O
brain	B-GENE
cholinesterase	I-GENE
(	O
ChE	B-GENE
)	O
activity	O
in	O
birds	O
is	O
often	O
used	O
to	O
diagnose	O
exposure	O
or	O
death	O
from	O
organophosphorus	O
or	O
carbamate	O
pesticides	O
.	O


Heating	O
cells	O
to	O
43	O
degrees	O
C	O
decreased	O
the	O
amount	O
of	O
newly	O
synthesized	O
rRNA	O
to	O
less	O
than	O
5	O
%	O
of	O
the	O
control	O
level	O
and	O
led	O
to	O
greater	O
than	O
95	O
%	O
inhibition	O
of	O
transcription	O
termination	O
at	O
a	O
region	O
355	O
to	O
362	O
nucleotides	O
downstream	O
of	O
the	O
3	O
'	O
end	O
of	O
28S	B-GENE
rRNA	I-GENE
,	O
with	O
readthrough	O
continuing	O
into	O
the	O
next	O
transcription	O
unit	O
.	O


